var title_f28_7_28784="Advanced calciphylaxis";
var content_f28_7_28784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Advanced calciphylaxis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Calciphylaxis of the leg in a patient with end-stage renal disease. Ischemic necrosis has led to both violaceous lesions and black, leathery eschar-like lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28784=[""].join("\n");
var outline_f28_7_28784=null;
var title_f28_7_28785="Tracheoesophageal fistula Endo";
var content_f28_7_28785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Tracheoesophageal fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel shows a view into the esophagus during endoscopy revealing a tracheoesophageal fistula. A covered, self-expanding metal stent has been deployed covering the fistula (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Todd H Baron, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28785=[""].join("\n");
var outline_f28_7_28785=null;
var title_f28_7_28786="Patient information: Anal pruritus (anal itching) (The Basics)";
var content_f28_7_28786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83428\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/23/20849\">",
"         Patient information: Anal abscess and fistula (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/15/41202\">",
"         Patient information: Hemorrhoids (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/33/9746\">",
"         Patient information: Pinworms (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/31/44529\">",
"         Patient information: Anal fissure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1730\">",
"         Patient information: Gonorrhea (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/47/40689\">",
"         Patient information: Hemorrhoids (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Anal pruritus (anal itching) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/anal-pruritus-anal-itching-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H94192156\">",
"      <span class=\"h1\">",
"       What is anal pruritus (anal itching)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anal pruritus is itching of the anus or the skin around it. The anus is the last part of the digestive system (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). It is where bowel movements leave the body.",
"     </p>",
"     <p>",
"      Anal itching can cause discomfort and embarrassment. Some people think it means they have colon cancer. But anal itching is usually caused by something else.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94192171\">",
"      <span class=\"h1\">",
"       What causes anal itching?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are many possible causes of anal itching, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Part of a bowel movement that gets stuck to the skin around the anus &ndash; This is more likely to happen if you have diarrhea or soft bowel movements.",
"       </li>",
"       <li>",
"        Hemorrhoids &ndash; These are swollen veins in the rectum. They can also cause pain. &nbsp;",
"       </li>",
"       <li>",
"        Certain foods or drinks, which can irritate the anus, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Coffee, tea, beer, and cola",
"       </li>",
"       <li>",
"        Chocolate",
"       </li>",
"       <li>",
"        Tomatoes",
"       </li>",
"       <li>",
"        Citrus fruits, such as oranges or grapefruit",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Diseases that affect the anus, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        An anal abscess &ndash; This is a lump that happens when a gland inside the anus gets infected.",
"       </li>",
"       <li>",
"        An anal fistula &ndash; This is a tunnel that forms between the anal gland and the place where the abscess is on the skin.",
"       </li>",
"       <li>",
"        Cancer &ndash; Some people who get anal, rectal, or colon cancer have anal itching.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Skin diseases, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Psoriasis &ndash; A skin condition that can cause a rash and itching.",
"       </li>",
"       <li>",
"        Dermatitis &ndash; A skin rash that can happen after your skin touches something that irritates it or something you are allergic to. This could be a skin cream, laundry detergent, or something else that touches the area around your anus.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Diseases caused by infection with a bacteria or fungus.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94192188\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to get rid of anal itching?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are some things you can try. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Keeping the anus and skin around it clean and dry &ndash; You can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Wipe gently after a bowel movement, using a moist pad or tissue",
"       </li>",
"       <li>",
"        NOT use a cleaning lotion, such as",
"        <a class=\"drug drug_general\" href=\"UTD.htm?14/34/14882?source=see_link\">",
"         witch hazel",
"        </a>",
"        &ndash; This can make symptoms worse. &nbsp;",
"       </li>",
"       <li>",
"        Take a bath after you have a bowel movement &ndash; Use mild, unscented soap. Pat the area dry with a soft towel or use a hair dryer on the cool setting. &nbsp;",
"       </li>",
"       <li>",
"        Put some unscented talcum powder on the skin around the anus &ndash; This can help keep the area dry.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Putting an anti-itch ointment on the area &ndash; You can use an over-the-counter",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?38/9/39056?source=see_link\">",
"         hydrocortisone",
"        </a>",
"        cream (sample brand names: Preparation H&reg;, Anu-med HC). But do not use anti-itch cream for more than 2 weeks.",
"       </li>",
"       <li>",
"        Putting a",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/25/14740?source=see_link\">",
"         zinc oxide",
"        </a>",
"        skin ointment or paste on the area (sample brand names: Desitin&reg;, Balmex&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the itching is worse at night, you can take medicines called antihistamines (sample brand names: Benadryl&reg;, Aler-Cap).",
"     </p>",
"     <p>",
"      You can also try NOT eating or drinking things that can cause anal itching or diarrhea. For example, some people get diarrhea when they drink milk or eat foods made with milk.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94192205\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse will do an exam and learn about your symptoms. You might also have the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Biopsy &ndash; If the doctor or nurse finds a growth, he or she will take a small sample of tissue from the area. Another doctor looks at the sample under a microscope to check for cancer.",
"       </li>",
"       <li>",
"        Colonoscopy &ndash; This test looks at the inside lining of a person&rsquo;s large intestine, called the &ldquo;colon.&rdquo; During a colonoscopy, the doctor puts a tube with a tiny camera into your anus and up to your colon. This lets the doctor look for cancer or other problems. Before a colonoscopy, you get medicine to make you relax.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94192222\">",
"      <span class=\"h1\">",
"       How is anal itching treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If a medical condition is causing the anal itching, doctors can treat that condition. This usually gets rid of the itching.",
"     </p>",
"     <p>",
"      A few people have anal itching even after trying different things to stop it. If this happens, doctors can give an injection (shot) of medicine to numb the area around the anus. This can stop the itching.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94192237\">",
"      <span class=\"h1\">",
"       Can anal itching be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting anal itching by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keeping the area around the anus clean and dry",
"       </li>",
"       <li>",
"        NOT eating foods that can cause anal itching or diarrhea",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94192252\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/15/41202?source=see_link\">",
"       Patient information: Hemorrhoids (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/23/20849?source=see_link\">",
"       Patient information: Anal abscess and fistula (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/33/9746?source=see_link\">",
"       Patient information: Pinworms (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=see_link\">",
"       Patient information: Anal fissure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=see_link\">",
"       Patient information: Hemorrhoids (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"       Patient information: Gonorrhea (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/7/28786?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83428 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-59F4F6E9F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28786=[""].join("\n");
var outline_f28_7_28786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94192156\">",
"      What is anal pruritus (anal itching)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94192171\">",
"      What causes anal itching?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94192188\">",
"      Is there anything I can do on my own to get rid of anal itching?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94192205\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94192222\">",
"      How is anal itching treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94192237\">",
"      Can anal itching be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94192252\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83428\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/23/20849?source=related_link\">",
"      Patient information: Anal abscess and fistula (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/31/44529?source=related_link\">",
"      Patient information: Anal fissure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=related_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=related_link\">",
"      Patient information: Hemorrhoids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/15/41202?source=related_link\">",
"      Patient information: Hemorrhoids (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/33/9746?source=related_link\">",
"      Patient information: Pinworms (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_7_28787="Effect activat mutation RET";
var content_f28_7_28787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    RET receptor tyrosine kinase: Effect of activating mutations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Effect of Cys634Arg mutation (MEN2A). B) Effect of Met918Thr mutation (MEN2B).",
"    <div class=\"footnotes\">",
"     GFRa: co-receptor glial cell line-derived neurotrophic factor-receptor family a",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28787=[""].join("\n");
var outline_f28_7_28787=null;
var title_f28_7_28788="Magnesium L-aspartate hydrochloride: Pediatric drug information";
var content_f28_7_28788=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium L-aspartate hydrochloride: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?30/12/30916?source=see_link\">",
"    see \"Magnesium L-aspartate hydrochloride: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/38/11876?source=see_link\">",
"    see \"Magnesium L-aspartate hydrochloride: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maginex&trade; DS [OTC];",
"     </li>",
"     <li>",
"      Maginex&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1022898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Magnesium Salt",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13292058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommended daily allowance of magnesium: Oral: 40 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1022911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/12/30916?source=see_link\">",
"      see \"Magnesium L-aspartate hydrochloride: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommended daily allowance of magnesium: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Magnesium &minus; Recommended Daily Allowance (RDA) and Estimated Average Requirement (EAR) (in terms of elemental magnesium)",
"     </caption>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         RDA",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         EAR",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1 to &lt;6 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         6 to &lt;12 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         65",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         4-8 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         110",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Male",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         9-13 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         240",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         14-18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         410",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         340",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Female",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         9-13 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         240",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         14-18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         360",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hypomagnesemia:",
"     <b>",
"      Note:",
"     </b>",
"     Achieving optimal magnesium levels using oral therapy may be difficult due to the propensity for magnesium to cause diarrhea: I.V. replacement may be more appropriate particularly in situations of severe deficit:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 10-20 mg/kg elemental magnesium per dose up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dietary supplement: Adults: 1230 mg up to 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Patients in severe renal failure should not receive magnesium due to toxicity from accumulation. Patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute receiving magnesium should have serum magnesium levels monitored.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for solution, oral [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maginex&trade; DS: 1230 mg/packet (30s) [sugar free; lemon flavor; equivalent to elemental magnesium 122 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated, oral [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maginex&trade;: 615 mg [sugar free; equivalent to elemental magnesium 61 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3013440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1022916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules: Mix each packet in 4 ounces water or juice prior to administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Take with full glass of water",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1022899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium supplement",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F190764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gastrointestinal: Abdominal cramps, diarrhea (excessive oral doses), gas formation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1022901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to magnesium salt(s) or any component; serious renal impairment, myocardial damage, heart block; patients with colostomy or ileostomy, intestinal obstruction, impaction, or perforation, appendicitis, abdominal pain",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3416800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function (accumulation of magnesium may lead to magnesium intoxication)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1022902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of magnesium exist; close attention must be paid to the salt form when ordering and administering magnesium;",
"     <b>",
"      incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3013482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Osada, 2002; Idama, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3416821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is important as a cofactor in many enzymatic reactions in the body. There are at least 300 enzymes which are dependent upon magnesium for normal functioning. Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol. Magnesium is necessary for the maintaining of serum potassium and calcium levels due to its effect on the renal tubule. In the heart, magnesium acts as a calcium channel blocker. It also activates sodium potassium ATPase in the cell membrane to promote resting polarization and produce arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3416823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Up to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal with unabsorbed drug excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3426367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium L-aspartate 500 mg = 49.6 mg",
"     <b>",
"      elemental",
"     </b>",
"     magnesium = 4.1 mEq magnesium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Magnesium Content of Magnesium Salts",
"     </caption>",
"     <col align=\"left\" width=\"190\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Magnesium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/500 mg salt)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/500 mg salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         27",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium L-aspartate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         49.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium oxide",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         302",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium sulfate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         49.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.1",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12968 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28788=[""].join("\n");
var outline_f28_7_28788=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190750\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022898\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13292058\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022911\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190741\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013440\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022916\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022899\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190764\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022901\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416800\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022902\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299636\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190738\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013482\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416821\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416823\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3426367\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12968\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12968|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/12/30916?source=related_link\">",
"      Magnesium L-aspartate hydrochloride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/38/11876?source=related_link\">",
"      Magnesium L-aspartate hydrochloride: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_7_28789="Norfloxacin: Patient drug information";
var content_f28_7_28789=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Norfloxacin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     see \"Norfloxacin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Noroxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Norflox&reg;;",
"     </li>",
"     <li>",
"      CO Norfloxacin;",
"     </li>",
"     <li>",
"      Norfloxacine&reg;;",
"     </li>",
"     <li>",
"      Novo-Norfloxacin;",
"     </li>",
"     <li>",
"      PMS-Norfloxacin;",
"     </li>",
"     <li>",
"      Riva-Norfloxacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of tendons getting irritated and tearing. The chance is greater in people over the age of 60; heart, kidney, or lung transplant patients; or people taking steroid drugs. Call your doctor right away if you have pain in the back of the ankle or joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you have myasthenia gravis. Very bad effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to norfloxacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had tendons get irritated or torn when taking this drug or an alike drug in the past.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697297",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low potassium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698530",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking theophylline, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take dairy products, antacids, didanosine, multivitamins, minerals (calcium, iron, zinc, magnesium), diet aids, or sucralfate within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698369",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tendons may rarely get irritated and tear.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain in back of the ankle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10916 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28789=[""].join("\n");
var outline_f28_7_28789=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202558\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202559\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023949\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023951\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023950\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023955\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023956\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023958\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023953\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023954\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023959\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023960\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=related_link\">",
"      Norfloxacin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_7_28790="Primary biliary cirrhosis IV - high power";
var content_f28_7_28790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary biliary cirrhosis in a 45-year-old man with pruritus (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A damaged bile duct is at the center of a lymphocytic infiltrate. This is the florid bile duct lesion that is characteristic of PBC.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28790=[""].join("\n");
var outline_f28_7_28790=null;
var title_f28_7_28791="Betamethasone: Pediatric drug information";
var content_f28_7_28791=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Betamethasone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"    see \"Betamethasone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/7/7287?source=see_link\">",
"    see \"Betamethasone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Celestone&reg;;",
"     </li>",
"     <li>",
"      Celestone&reg; Soluspan&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg; AF;",
"     </li>",
"     <li>",
"      Luxiq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Betaderm;",
"     </li>",
"     <li>",
"      Betaject&trade;;",
"     </li>",
"     <li>",
"      Betnesol&reg;;",
"     </li>",
"     <li>",
"      Betnovate&reg;;",
"     </li>",
"     <li>",
"      Celestone&reg; Soluspan&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg; Glycol;",
"     </li>",
"     <li>",
"      Diprosone&reg;;",
"     </li>",
"     <li>",
"      Ectosone;",
"     </li>",
"     <li>",
"      Prevex&reg; B;",
"     </li>",
"     <li>",
"      ratio-Ectosone;",
"     </li>",
"     <li>",
"      Ratio-Topilene;",
"     </li>",
"     <li>",
"      ratio-Topilene;",
"     </li>",
"     <li>",
"      Ratio-Topisone;",
"     </li>",
"     <li>",
"      ratio-Topisone;",
"     </li>",
"     <li>",
"      Rivasone;",
"     </li>",
"     <li>",
"      Rolene;",
"     </li>",
"     <li>",
"      Rosone;",
"     </li>",
"     <li>",
"      Taro-Sone;",
"     </li>",
"     <li>",
"      Valisone&reg; Scalp Lotion",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"      see \"Betamethasone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Base dosage on severity of disease and patient response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Use lowest dose listed as initial dose for adrenocortical insufficiency (physiologic replacement); 0.0175-0.125 mg base/kg/day divided every 6-12 hours",
"     <b>",
"      or",
"     </b>",
"     0.5-7.5 mg base/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults: 0.6-9 mg/day divided every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Use lowest dose listed as initial dose for adrenocortical insufficiency (physiologic replacement); 0.0175-0.25 mg/kg/day divided every 6-8 hours",
"     <b>",
"      or",
"     </b>",
"     0.5-7.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults: 2.4-4.8 mg/day in 2-4 doses; range: 0.6-7.2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Use smallest amount for shortest period of time to avoid HPA suppression; discontinue use once control is achieved; reassess diagnosis if no improvement is seen within 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults: Apply thin film 1-2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;13 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Diprolene&reg; AF cream: Apply thin film 1-2 times/day; maximum: 45 g of cream/week; do not use &gt;2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Diprolene&reg; Lotion: Apply a few drops once or twice daily; maximum: 50 mL/week; do not use &gt;2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Diprolene&reg; Gel: Apply thin film once or twice daily; maximum: 50 g/week; do not use &gt;2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;16 years and Adults: Luxiq&reg; foam: Apply twice daily (in morning and at night)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical, as valerate: 0.12% (50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Luxiq&reg;: 0.12% (50 g, 100 g) [contains ethanol 60.4%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as dipropionate [strength expressed as base]: 0.05% (15 g, 45 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as dipropionate [strength expressed as base, augmented]: 0.05% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diprolene&reg; AF: 0.05% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as valerate [strength expressed as base]: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as dipropionate [strength expressed as base, augmented]: 0.05% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension: Betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Celestone&reg; Soluspan&reg;: Betamethasone sodium phosphate 3 mg and betamethasone acetate 3 mg per 1 mL (5 mL) [contains benzalkonium chloride, edetate disodium; total of 6 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as dipropionate [strength expressed as base]: 0.05% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as dipropionate [strength expressed as base, augmented]: 0.05% (30 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diprolene&reg;: 0.05% (30 mL, 60 mL) [contains isopropyl alcohol 30%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as valerate [strength expressed as base]: 0.1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as dipropionate [strength expressed as base]: 0.05% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as dipropionate [strength expressed as base, augmented]: 0.05% (15 g, 45 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diprolene&reg;: 0.05% (15 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as valerate [strength expressed as base]: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Celestone&reg;: 0.6 mg/5 mL (118 mL) [contains ethanol &lt;1%, propylene glycol, sodium benzoate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food to decrease GI effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Do not administer injectable suspension I.V.; shake injectable suspension before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply sparingly, rub in gently until it disappears; do not apply to face, axillae,  or inguinal areas; not for use on broken skin, in areas of infection, or in diaper area. Do not apply to wet skin unless directed; do not cover with occlusive dressing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Foam: Invert can, dispense small amount of foam onto saucer or other cool surface; foam will melt upon contact with warm skin (do not dispense directly into hands); use fingers to apply small amounts of foam to affected scalp area; rub in gently until it disappears; avoid fire, flame, or smoking during use; contents of can are flammable and under pressure",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F140698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature; foam canister is flammable; avoid fire, flame, heat; do not store at &gt;120&deg;F (49&deg;C)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-inflammatory; immunosuppressant agent; corticosteroid replacement therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Inflammatory dermatoses such as psoriasis, seborrheic or atopic dermatitis, neurodermatitis, inflammatory phase of xerosis, late phase of allergic dermatitis or irritant dermatitis; Foam: Inflammatory and pruritic symptoms of scalp dermatoses responsive to corticosteroids",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Luxiq&reg; may be confused with Lasix&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Beta-Val [U.S.] may be confused with Betanol brand name for metipranolol [Monaco]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F140697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Systemic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Congestive heart failure, edema, hyper-/hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, insomnia, intracranial pressure increased, lightheadedness, nervousness, pseudotumor cerebri, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Ecchymoses, facial erythema, fragile skin, hirsutism, hyper-/hypopigmentation, perioral dermatitis (oral), petechiae, striae, wound healing impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, Cushing's syndrome, diabetes mellitus, growth suppression, hyperglycemia, hypokalemia, menstrual irregularities, pituitary-adrenal axis suppression, protein catabolism, sodium retention, water retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appetite increased, hiccups, indigestion, peptic ulcer, pancreatitis, ulcerative esophagitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (intra-articular use), sterile abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, fractures, muscle atrophy, muscle weakness, myopathy, osteoporosis, necrosis (femoral and humeral heads)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, glaucoma, intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction, diaphoresis, hypersensitivity, secondary infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Topical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acneiform eruptions, allergic dermatitis, burning, dry skin, erythema, folliculitis, hypertrichosis, irritation, miliaria, pruritus, skin atrophy, striae, vesiculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine and metabolic effects have occasionally been reported with topical use.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to betamethasone or any component; systemic fungal infections",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth). Use with extreme caution in patients with respiratory tuberculosis or untreated systemic infections. Use with caution in patients with hypertension, heart failure, or renal impairment; long-term use has been associated with fluid retention and hypertension. Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to risk of GI bleeding and perforation. High-dose corticosteroids should not be used for management of head injury; increased mortality was observed in patients receiving high-dose I.V. methylprednisolone. Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids. Use with caution in patients with hepatic impairment, including cirrhosis; enhanced pharmacologic effect due to decreased metabolism and long-term use has been associated with fluid retention. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use with caution in patients with diabetes; corticosteroids may alter glucose regulation, leading to hyperglycemia. Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use; consider routine eye exams in chronic users. Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis. Use with caution in patients with thyroid dysfunction; changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients. Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered. Use with caution in patients with thromboembolic tendencies or thrombophlebitis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use topical products sparingly in children, systemic effects may be seen;",
"     <b>",
"      Note:",
"     </b>",
"     Due to the high incidence of developing adrenal suppression,  augmented topical products (eg, Diprolene&reg; AF cream, Diprolene&reg; lotion) are not recommended for use in children &le;12 years of age. Foam is not recommended for children &lt;16 years.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2985532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be tapered slowly and carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Immunosuppression may occur; patients may be more susceptible to infections; prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral or fungal infections, activate latent opportunistic infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use. Acute myopathy may occur with high doses, usually in patients with neuromuscular transmission disorders; myopathy may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed. Increased IOP may occur, especially with prolonged use; in children, increased IOP has been shown to be dose-dependent and produce a greater IOP in children &lt;6 years than older children (Lam, 2005). Rare cases of anaphylactoid reactions have been reported with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Topical: Infants and small children may be more susceptible to HPA axis suppression from topical corticosteroid therapy; systemic effects may occur when used on large areas of the body, denuded areas, for prolonged periods of time, or with an occlusive dressing; do not use in diaper area or with occlusive dressings, especially on weeping or exudative lesions; discontinue if skin irritation or contact dermatitis occurs; do not use very high potency topical products for the treatment of rosacea or perioral dermatitis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral solution contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of betamethasone products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Oral solution contains propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities, which can include metabolic acidosis, seizures, renal failure, and CNS depression; use dosage forms containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F140684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B",
"     <sub>",
"      6",
"     </sub>",
"     , C, D, folate, calcium, zinc, and phosphorus and decreased sodium",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F140631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Betamethasone crosses the placenta; approximately 25% is metabolized by placental enzymes to an inactive metabolite. Due to its positive effect on stimulating fetal lung maturation, a single course of the injection is often used in patients with premature labor (24-34 weeks gestation) who are expected to deliver within 7 days. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Women exposed to betamethasone during pregnancy for the treatment of an autoimmune disease may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and causes lysosomal stabilization at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 64%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;5% of dose excreted renally as unchanged drug; small amounts eliminated via biliary tract",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/7/7287?source=see_link\">",
"      see \"Betamethasone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Systemic use: Avoid alcohol and caffeine; do not decrease dose or discontinue without physician's approval",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical use: Avoid contact with eyes; do not use occlusive dressings or other corticosteroid-containing products unless directed by physician",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-acting corticosteroid with minimal or no sodium-retaining potential. Topical products: Very high potency: Augmented betamethasone dipropionate ointment and lotion; high potency: Augmented betamethasone dipropionate cream and betamethasone dipropionate cream and ointment; intermediate potency: Betamethasone dipropionate lotion and betamethasone valerate cream. Topical products labeled as augmented use a vehicle that augments (increases) the penetration of the drug into the skin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Several recent studies conducted in children &le;12 years of age with atopic dermatitis demonstrated a high incidence of adrenal suppression when topical betamethasone products were applied twice daily for 2-3 weeks. Adrenal suppression occurred in 19 of 60 (32%) evaluable patients (3 months to 12 years of age) using Diprolene&reg; AF cream 0.05%. A higher percent incidence of adrenal suppression was noted in younger children and infants (see product package insert). Pediatric patients may be more susceptible to adrenal suppression and other systemic side effects of topical corticosteroids, due to their larger skin surface area to body weight ratio. The smallest effective dose of topical corticosteroids should be used in pediatric patients.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review). American Academy of Pediatrics Committee on Drugs,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/7/28791/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam DS, Fan DS, Ng JS, et al, \"Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial,\"",
"      <i>",
"       Clin Experiment Ophthalmol",
"      </i>",
"      , 2005, 33(3):252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/7/28791/abstract-text/15932528/pubmed\" id=\"15932528\" target=\"_blank\">",
"        15932528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard MB, \"Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119 Suppl 2:S166-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/7/28791/abstract-text/17332238/pubmed\" id=\"17332238\" target=\"_blank\">",
"        17332238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13046 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28791=[""].join("\n");
var outline_f28_7_28791=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140644\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140645\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051333\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051326\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140621\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140608\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051337\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140698\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051330\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051336\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140700\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140697\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051340\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051325\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985532\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140684\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140617\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051342\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140618\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140631\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051324\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051339\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051332\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051341\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13046\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13046|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=related_link\">",
"      Betamethasone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/7/7287?source=related_link\">",
"      Betamethasone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_7_28792="Frailty";
var content_f28_7_28792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Frailty",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/7/28792/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28792/contributors\">",
"     Jeremy D Walston, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/7/28792/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28792/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/7/28792/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28792/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/7/28792/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the population ages, recognition of frailty in older adults becomes increasingly important. The potential to tailor medical care for the older patient to prevent frailty, to intervene to improve outcomes, and to recognize when palliation is appropriate are important components of geriatric care.",
"   </p>",
"   <p>",
"    Frailty is often conceptualized by health care providers as a state of late life decline and vulnerability characterized by weakness and decreased physiologic reserve. Frail older adults are less able to adapt to stressors such as acute illness or trauma. This increased vulnerability contributes to increased risk for falls, institutionalization, disability, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most medical practitioners who care for older adults have noted a subset of patients who are clearly in a state of rapid decline, seemingly unrelated to a specific disease state. Other patients who are frail have more subtle signs and symptoms that can be easily overlooked.",
"   </p>",
"   <p>",
"    Old age itself does not define frailty. Some patients, despite advanced age, may experience temporary disability related to illness or trauma, but rebound after recovery and return to their baseline. Others may appear robust but tolerate medical stress poorly, and never regain full function following illness or hospitalization. Still others are noted to have gradual but unrelenting functional decline in the absence of apparent stress factors.",
"   </p>",
"   <p>",
"    Frail older adults represent a challenge to clinicians because they usually present with an increased burden of symptoms, are often medically complex, and are less able to tolerate interventions of any kind. Clinician awareness of the frailty syndrome, its biologic basis, and the increased risk for adverse outcomes can improve care for this most vulnerable subset of patients.",
"   </p>",
"   <p>",
"    This topic will review the conceptualization and definition of frailty, the underlying biologic processes, and clinical interventions that may attenuate the vulnerability and relieve some symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early identification of frailty has the potential to prevent many adverse health care outcomes. However, while it is recognized that the term 'frailty' captures the essence of age-related vulnerability and decline, no single clinical definition of frailty has been accepted and put into clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors complicate the formulation of a definition for frailty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/3\">",
"     3",
"    </a>",
"    ]. Older adults come from heterogeneous medical, environmental, educational, and psychological backgrounds, so that considerable variation is present in baseline status. Additionally, frailty exists on a spectrum, further increasing the complexity of defining the condition. The end stage of the continuum of frailty is failure to thrive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34215?source=see_link\">",
"     \"Failure to thrive in elderly adults: Evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42455?source=see_link\">",
"     \"Failure to thrive in elderly adults: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most definitions of frailty describe a syndrome that is marked by loss of function, strength, physiologic reserve, with increased vulnerability to morbidity and mortality. A 2004 American Geriatrics",
"    <span class=\"nowrap\">",
"     Society/National",
"    </span>",
"    Institute on Aging conference on frailty in older adults describes frailty as \"a state of increased vulnerability to stressors due to age-related declines in physiologic reserve across neuromuscular, metabolic, and immune systems\" [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/4\">",
"     4",
"    </a>",
"    ]. Other definitions include alterations in mobility, strength, endurance, nutrition, and physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Still others utilize a tally of medical, physiologic, cognitive, and social factors that are not biologically related to calculate a frailty index that predicts mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Age, chronic comorbidities, and disability are often associated with frailty, but there is evidence that frailty can exist independently of these factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/3,5,10,11\">",
"     3,5,10,11",
"    </a>",
"    ]. These characteristics have not, therefore, been integrated into most definitions of frailty, and many consider disability to be an outcome, rather than a component, of frailty.",
"   </p>",
"   <p>",
"    Many definitions of frailty do not incorporate cognitive assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/12\">",
"     12",
"    </a>",
"    ], although this is under debate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/2\">",
"     2",
"    </a>",
"    ]. A 2011 systematic review of 22 articles addressing the definition of frailty found that the most commonly used measurements for frailty screening were physical function, gait speed, and cognition. Physical frailty is associated with an increased risk of mild cognitive impairment and an increased rate of cognitive decline with aging [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/13\">",
"     13",
"    </a>",
"    ]. Additionally, the presence of cognitive impairment increases the likelihood of adverse health outcomes in geriatric patients who meet criteria for physical frailty.",
"   </p>",
"   <p>",
"    Some of the more commonly used definitions of frailty are the Cardiovascular Health Study (CHS) or Fried Frailty index, the Study of Osteoporotic Fractures (SOF) index, and the Rockwood Frailty Index. Several studies have compared criteria and found that these indices were comparable in predicting risk of adverse health outcomes and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cardiovascular Health Study index",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definition, widely used in research protocols and validated in the Cardiovascular Health Study (CHS) of over 5000 men and women aged 65 and older, defines the frailty phenotype as meeting three or more of the following five criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/5\">",
"     5",
"    </a>",
"    ]. Prefrailty is defined as fewer than three characteristics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight loss (&ge;5 percent of body weight in last year)",
"     </li>",
"     <li>",
"      Exhaustion (positive response to questions regarding effort required for activity)",
"     </li>",
"     <li>",
"      Weakness (decreased grip strength)",
"     </li>",
"     <li>",
"      Slow walking speed (gait speed) (&gt;6 to 7 seconds to walk 15 feet)",
"     </li>",
"     <li>",
"      Decreased physical activity (Kcals spent per week: males expending &lt;383 Kcals and females &lt;270 Kcal)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three of these criteria (weight loss, slow walking speed, and low physical activity), as well as cognitive impairment, were independently associated with disability, long-term nursing home residence, and death in a longitudinal study of 754 adults aged 70 and older, initially non-disabled and living in the community, and followed for six years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/17\">",
"     17",
"    </a>",
"    ]. These frailty criteria also have been demonstrated to independently predict postoperative complications, length of stay, and discharges to a skilled or assisted-living facility in older adults undergoing surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The five domains of this tool have also been adapted by a Survey of Health, Ageing, and Retirement in Europe (SHARE) in a way that can be more readily measured in a clinical setting with similar predictive values for mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Study of Osteoporotic Fractures index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the criteria used in the CHS index are not readily assessed in the non-research clinical setting. An index that is easier to use, the Study of Osteoporotic Fractures (SOF) index, defines frailty as the presence of at least two of three components [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight loss of 5 percent in last year",
"     </li>",
"     <li>",
"      Inability to rise from a chair five times without use of arms, or",
"     </li>",
"     <li>",
"      A \"no\" response to the question \"Do you feel full of energy?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1300407706\">",
"    <span class=\"h2\">",
"     Rockwood frailty index",
"    </span>",
"    &nbsp;&mdash;&nbsp;This index uses 70 variables that range from medical conditions to functional decline [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/20\">",
"     20",
"    </a>",
"    ]. The higher the score in this index, the more frail the individual. This index is especially well suited for mortality risk assessment using information from electronic medical records because it uses historical measurements rather than any physical measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1300407734\">",
"    <span class=\"h1\">",
"     FRAILTY AS A RISK ASSESSMENT TOOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past several years, a plethora of frailty screening tools have been developed and used to identify older adults who are at highest risk of adverse health outcomes. Many of these assessment tools have evolved from the three validated tools described above. Although there is no clear consensus on which tool is the best, a number of studies have used measures of frailty to not only assess risk of mortality and other adverse outcomes, but also to study the influence that frailty might have on specific diseases or interventions. For example, one study demonstrated that frail older adults are much less likely to mount an adequate immune response to influenza vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/21\">",
"     21",
"    </a>",
"    ]. Frailty also predicted adverse outcomes related to renal transplantation and to general surgery interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/18,22\">",
"     18,22",
"    </a>",
"    ]. These and other studies highlight the potential utility of using frailty status to estimating adverse outcomes in a wide variety of clinical settings. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many epidemiologic studies of frailty have been performed, using a variety of frailty measures. Using the most commonly applied frailty measure, initially validated in the CHS population (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above), one study showed that approximately 7 percent of the community-dwelling population was frail, 44 percent intermediate, and 46 percent non-frail [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/5\">",
"     5",
"    </a>",
"    ]. The prevalence of frailty was even higher in the Women's Health and Aging population, with up to 11.3 percent of this population meeting frailty criteria at the baseline assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/23\">",
"     23",
"    </a>",
"    ]. Frailty prevalence increases with age, so that up to 30 percent of the population meets frailty criteria by age 90 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/24\">",
"     24",
"    </a>",
"    ]. A systematic review found that studies reported wide variation in prevalence of frailty in the community depending on the definition used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/25\">",
"     25",
"    </a>",
"    ]. When frailty was defined on the basis of physical findings alone, overall prevalence for 15 studies (44,894 participants) was 9.9 percent; when psychosocial aspects were included in the definition, prevalence was 13.6 percent among eight studies (24,072 participants).",
"   </p>",
"   <p>",
"    Other studies using similar definitions of frailty have shown similar results. Data from the Women's Health Initiative Observational Study, involving over 40,000 women aged 65 to 70 at baseline, found that baseline frailty (using CHS criteria) was present in 16.3 percent, and prefrailty was identified in 28.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/26\">",
"     26",
"    </a>",
"    ]. Incident frailty at three years was 14.8 percent. Women who became frail were older, less educated, and more likely to be current smokers or current hormone therapy users. Mortality was increased in those with baseline frailty (HR 1.71; 95% CI 1.48-1.97). Frailty also predicted hip fractures, disability, and hospitalization after adjustment for comorbidities.",
"   </p>",
"   <p>",
"    A study in the United States of nearly 6000 community-dwelling men aged 65 and older found that 4 percent met criteria for frailty, 40 percent for prefrailty, and 56 percent were robust [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/27\">",
"     27",
"    </a>",
"    ]. Frailty was defined using criteria similar to the CHS definition (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above) except that low appendicular skeletal mass was substituted for weight loss.",
"   </p>",
"   <p>",
"    Frailty in this sample was more common in African Americans and Asians than Caucasians and Hispanics (6.6, 5.8, 3.8, and 2.4 percent respectively). Mortality was twice as high for frail men than robust men (HR 2.05; 95% CI 1.55-2.72). Frail men were older than pre-frail or robust men (mean ages 79, 74.9, and 72.4 respectively), more likely to be unmarried, and less educated. Frailty was present in 1.6 percent of men aged 65 to 69, and 11.1 percent of men aged 80 and older. At follow-up (average 4.6 years), 54.4 percent of men who were robust at baseline remained robust, 25.3 percent became prefrail, and 1.6 percent frail (5.7 percent died and the remainder could not be assessed).",
"   </p>",
"   <p>",
"    The prevalence of frailty is increased in individuals with intellectual disability (ID); the prevalence among this population at age 50 to 64 was the same as in the general population 65 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/28\">",
"     28",
"    </a>",
"    ]. Depression and use of antidepressants is also associated with an increased incidence of frailty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progress has been made in the identification of biologic and physiologic factors that underlie frailty and in understanding the vulnerability to adverse outcomes of frail older adults. Dysregulation in multiple physiologic systems, especially stress response systems, is a key feature of frailty. The basis of this dysregulation is likely related to age-related molecular changes, genetics, and specific disease states. The complex biology underlying frailty is depicted in a model that outlines molecular, genetic, and chronic disease contributions to the frailty phenotype, clinical conditions often observed in frailty, and resulting adverse health outcomes (",
"    <a class=\"graphic graphic_figure graphicRef60373 \" href=\"UTD.htm?7/22/7535\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific physiologic abnormalities are thought to contribute to frailty symptoms, based on models from diseases such as cancer or rheumatoid arthritis where muscle weakness and fatigue are common symptoms. The stress response systems that figure most prominently in studies of the pathophysiology of frailty include the inflammatory and endocrine pathways, which in turn contribute to declines in skeletal muscle. Sarcopenia, or age-related loss of skeletal muscle and muscle strength, is a key physiologic component of frailty. Hormonal changes discussed below (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Endocrine'",
"    </a>",
"    below), including lower levels of IGF-1 and DHEA-S, and higher levels of cortisol, have been demonstrated to directly influence skeletal muscle decline and likely influence the development of frailty as well [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Inflammatory cytokines likely also contribute to sarcopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endocrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of sarcopenia (age-related decline in muscle function) suggest that alterations in the endocrine system likely play a role in the accelerated decline in muscle mass and strength seen in frail older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple hormone changes that occur with aging have been associated with frailty (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12650?source=see_link\">",
"     \"Endocrine changes with aging\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decline in sex steroids occur with increasing age and have been hypothesized to contribute to frailty. Although evidence is mixed, there is at least some evidence that lower levels of reproductive hormones contribute to frailty [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/35-37\">",
"       35-37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No association was found between total or free testosterone and the frailty phenotype (defined by the CHS criteria) (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above), after adjusting for confounding factors [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/38\">",
"       38",
"      </a>",
"      ]. However, levels of sex hormone binding globulin were associated with frailty. Low testosterone levels were associated with decreased strength and physical activity.",
"     </li>",
"     <li>",
"      Growth hormone levels decrease with age, as do peaks of production in early morning [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. Levels of insulin-like growth factor-1 (IGF-1), a growth hormone stimulated messenger molecule, are lower in frail compared to non-frail older adults [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/30\">",
"       30",
"      </a>",
"      ]. Lower levels of IGF-1 have been associated with lower strength and decreased mobility in a cohort of community dwelling older women [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The adrenal androgen dehydroepiandrosterone sulfate (DHEA-S) has been found to be significantly lower in frail compared to non-frail individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/30\">",
"       30",
"      </a>",
"      ]. DHEA-S likely plays a direct role in maintaining muscle mass and indirectly prevents the activation of inflammatory pathways that contribute to muscle decline [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cortisol levels are higher in the late afternoon in frail compared to nonfrail [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/43\">",
"       43",
"      </a>",
"      ]. These higher levels may, over time, impact skeletal muscle and immune system components, and thus compound frailty.",
"     </li>",
"     <li>",
"      Low 25(OH)D was strongly associated with frailty in a large cohort of older Dutch men and women [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/44\">",
"       44",
"      </a>",
"      ]. Vitamin D supplementation has been demonstrated to preserve muscle strength and may prove to play a role in preventing or treating frailty [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inflammation and the immune system",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the strongest and most consistent relationships between frailty and biological correlates comes from studies of biomarkers of the innate immune system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum levels of the pro-inflammatory cytokine IL-6 and C-reactive protein (CRP), as well as white blood cell and monocyte counts, are elevated in community-dwelling frail older adults [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/30,44,46,47\">",
"       30,44,46,47",
"      </a>",
"      ]. IL-6 acts as a transcription factor and signal transducer that adversely impacts skeletal muscle, appetite, adaptive immune system function, and cognition [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/48\">",
"       48",
"      </a>",
"      ]. Chronic elevation in IL-6 likely contributes to anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Activation of the innate immune system may contribute to the triggering of the clotting cascades. An association between frailty and clotting markers (factor VIII, fibrinogen and D-dimer) has been demonstrated [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1300407959\">",
"    <span class=\"h2\">",
"     Other stress response and metabolic systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study highlighted the relationship between frailty and dysregulated autonomic nervous system control [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, increasing evidence suggests that age-related changes in the renin-angiotensin system likely impacts sarcopenia and inflammation, important components of frailty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/52\">",
"     52",
"    </a>",
"    ]. There is increasing evidence that dysregulated immune, endocrine, stress, and energy response systems are important to the development of frailty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatments targeting underlying functional and biologic alterations associated with frailty have not been specifically evaluated. However, interventions developed for older adults can be reasonably applied to patients with frailty.",
"   </p>",
"   <p>",
"    Management of weight loss in this population is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42455?source=see_link&amp;anchor=H4#H4\">",
"     \"Failure to thrive in elderly adults: Management\", section on 'Weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Exercise and nutrition interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is believed to be the most effective of all interventions proposed to improve quality of life and functionality in older adults. The demonstrated benefits of exercise in older adults include increased mobility, enhanced performance of activities of daily living (ADL), improved gait, decreased falls, improved bone mineral density and increased general well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9161?source=see_link&amp;anchor=H96786655#H96786655\">",
"     \"Physical activity and exercise in older adults\", section on 'Benefits of physical activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of exercise and weight loss diet as one arm of a randomized trial for obese older adults had greater impact on measures of frailty (strength, balance gait, scores on the Physical Performance Test, peak oxygen consumption) than either intervention alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased muscle strength occurs normally with age but is even more pronounced in the frail older adult and is more likely to impact adverse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/58\">",
"     58",
"    </a>",
"    ]. Studies suggest that even the frailest oldest adults are likely to benefit from physical activity at almost any level that can be safely tolerated. Representative studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A program of resistance training in nursing home residents (mean age of 87) doubled muscle strength, and slightly but significantly increased lower extremity muscle size and gait velocity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/59\">",
"       59",
"      </a>",
"      ]. These changes were associated with increased mobility and spontaneous physical activity. Nutritional supplementation appeared to be helpful only when combined with exercise. &nbsp;",
"     </li>",
"     <li>",
"      In another study of resistance training, benefit was reported for exercise activity on as few as two days per week [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Walking as little as a mile in a one-week period was associated with a slower progression of functional limitations over a follow-up period of six months in an observational study [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hormonal/supplemental interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of inflammatory pathways and dysregulation in endocrine systems may contribute to frailty (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Pathophysiology'",
"    </a>",
"    above). Pharmacological interventions that target this pathophysiology have been considered. To date, hormonal and anti-inflammatory interventions for frailty have not been extensively studied. However, several hormonal and nutritional interventions have been tested for efficacy in other related geriatric conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testosterone replacement increased muscle mass and strength in hypogonadal and eugonadal men, especially in combination with exercise. Testosterone, however, may lead to an unfavorable lipid profile and unpredictable effects on the prostate gland [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Growth hormone or growth hormone releasing factor supplementation have not demonstrated efficacy in improving function or other clinical outcomes in older adults with age-related declines [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benefit from DHEA-S supplementation in preventing or treating frailty has not been demonstrated [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin D supplementation is effective for fall prevention and improving balance. In one report, lower serum levels of 25-hydroxyvitamin D (&lt;20.0",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      were associated with a higher prevalence of frailty at baseline in a group of 1600 men over age 65, but did not predict greater risk for developing frailty at 4.6 years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/66\">",
"       66",
"      </a>",
"      ]. Given that vitamin D appears to play an important role in both muscle and nervous tissue maintenance with aging, further studies are indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8393?source=see_link\">",
"       \"Prevention of falls and complications of falls in community-dwelling older persons\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further intervention studies will be needed to determine the effectiveness and potential harm of treatments that target endocrine or inflammatory biology in frail older adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MODEL SYSTEMS OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Care for frail older adults is frequently challenging, as a result of their increased disability, multiple chronic disease states, and further heightened because commonly they lack social supports. An interdisciplinary team-based approach to care is often important in meeting their needs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/67\">",
"     67",
"    </a>",
"    ]. Frail older adults may be the population most likely to benefit from specialized and targeted comprehensive interventions.",
"   </p>",
"   <p>",
"    A conceptual model of care has been outlined by one gerontology group, that proposes several adjuncts and enhancements to the traditional one",
"    <span class=\"nowrap\">",
"     physician/one",
"    </span>",
"    patient visit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/68\">",
"     68",
"    </a>",
"    ]. Proposed practice changes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Co-management involving physician and nurse practitioner or physician assistant",
"     </li>",
"     <li>",
"      Support personnel (nurses, social workers) with specialized gerontology training available as consultants",
"     </li>",
"     <li>",
"      Facilities accommodations: adjustable height tables, clearance for wheelchair maneuvering,",
"      <span class=\"nowrap\">",
"       microphones/headsets",
"      </span>",
"      for hearing impaired, adjustable walker",
"     </li>",
"     <li>",
"      General staff education for communicating with frail older adults",
"     </li>",
"     <li>",
"      Team meetings to discuss complicated patients",
"     </li>",
"     <li>",
"      Full integration of electronic communications: electronic medical records, e-mail, secure practice website, patient health questionnaires, templated notes",
"     </li>",
"     <li>",
"      Possible block scheduling with team members in one hour intervals, to better manage patient flow",
"     </li>",
"     <li>",
"      Partnership and familiarity with community resources for housing, health promotion, and caregiver support",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Comprehensive geriatric assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall goals of geriatric assessment are: to improve physical and psychological function; to optimize medication prescribing and use; to decrease nursing home placement, hospitalization, mortality risk; and to improve patient satisfaction. Comprehensive geriatric assessment (CGA) involves an interdisciplinary care team that coordinates evaluation of an older patient and develops a plan for integrated care [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/69\">",
"     69",
"    </a>",
"    ]. The team usually consists of a geriatrician or other medical practitioner knowledgeable in the care of older adults, nurse, social worker, pharmacist, and an occupational or physical therapist. Frail older adults are at highest risk in the general population of older adults and may be expected to derive maximum benefit from CGA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43624?source=see_link\">",
"     \"Comprehensive geriatric assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Outpatient PACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frailest older adults may benefit from the program for all-inclusive care for the elderly (PACE). The goals of this model are to improve function, overcome environmental challenges and keep older adults living in their communities by preventing institutionalization.",
"   </p>",
"   <p>",
"    In this outpatient patient management model, primary care is delivered to community-dwelling older adults by an interdisciplinary team in a day clinic setting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/70\">",
"     70",
"    </a>",
"    ]. The interdisciplinary team includes a practitioner knowledgeable in geriatric medicine, nurses, physical and occupational therapists, and social workers. Some of the services provided include home nursing, physical and occupational therapy, transportation, aide service, and adult day care. Patients who enter the program receive complete long term care and are followed until the end of their lives, even if they eventually require placement in an assisted-living facility or nursing home.",
"   </p>",
"   <p>",
"    PACE was designated as a permanent Medicare program in 1997 because it was successful in maintaining function and community-dwelling status and in providing lower cost care compared with traditional fee-for-service care [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hospital care and ACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hospital setting can be a significant source of morbidity for a frail older adult. Change in environment, exposure to new medications, and immobility, combined with acute illness, can lead to devastating outcomes for these vulnerable patients. Often, the decline in level of function and ability to care for oneself that occurs during hospitalization persists after discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. In one study, frail individuals had a seven-fold increased risk of progressing from no disability to mild disability within one month of hospitalization, compared to nonfrail patients (35 versus 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/74\">",
"     74",
"    </a>",
"    ]. Hospitalization increases risk for institutionalization and a decrease in quality of life.",
"   </p>",
"   <p>",
"    Acute Care for Elders (ACE) is a model of care for the acutely ill hospitalized older adult designed to prevent functional decline and improve functional independence if decline has occurred. The model typically includes a specially designed environment that is a more home-like environment; patient-centered medical care that focuses on the prevention of disability; and comprehensive discharge planning and management [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/75\">",
"     75",
"    </a>",
"    ]. In a randomized controlled trial of 1531 community-dwelling adults aged 70 and older, this model was shown to decrease the likelihood of ADL decline or nursing home placement both at hospital discharge and at 12 months without an increase in hospital length of stay or hospital costs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TAILORING INDIVIDUAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the older adult progresses along the frailty spectrum and develops more severe disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disability, it is important to tailor medical care to the needs of these vulnerable patients while keeping the individual's values and goals in mind. Potential interventions that might be beneficial along the continuum of frailty are shown in a figure (",
"    <a class=\"graphic graphic_figure graphicRef59326 \" href=\"UTD.htm?28/34/29230\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For robust older patients, the medical practitioner should appropriately treat known chronic diseases, manage intermittent acute illness and events, and assure age-appropriate screening measures and preventive care [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the moderately to severely frail patient, often \"less is more.\" Aggressive screening or intervention for non-life threatening conditions may be rife with complications. Procedures or hospitalizations may bring about unnecessary burden and decreased quality of life to a patient who is already at great risk of morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28792/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frailty is an increasingly recognized clinical state of vulnerability with inherent increased risk for adverse health outcomes, including functional decline and mortality. No consensus or commonly utilized clinical screening examination or diagnostic criteria have to date been implemented in clinical practice. Frailty is an independent predictor of surgical risk. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physiological basis of frailty is thought to be driven by the activation of inflammatory pathways and dysregulation of neuroendocrine systems, which leads to skeletal muscle decline. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventions to date have not focused on frailty per se, but rather on components of frailty, such as strength. Although exercise is the only intervention that has been shown to have a positive impact on even the frailest older adults, biologically targeted interventions may play a role in the future. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical geriatric evaluation teams and specialized programs can play an important role in improving the quality of life for older adults. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Model systems of care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to tailor interventions to the individual, incorporating patient preferences and stage on the spectrum of frailty (",
"      <a class=\"graphic graphic_figure graphicRef59326 \" href=\"UTD.htm?28/34/29230\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Tailoring individual care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/1\">",
"      Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 2013; 381:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/2\">",
"      Sternberg SA, Wershof Schwartz A, Karunananthan S, et al. The identification of frailty: a systematic literature review. J Am Geriatr Soc 2011; 59:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/3\">",
"      Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999; 130:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/4\">",
"      Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 2006; 54:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/5\">",
"      Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/6\">",
"      Ferrucci L, Guralnik JM, Studenski S, et al. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc 2004; 52:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/7\">",
"      Chin A Paw MJ, Dekker JM, Feskens EJ, et al. How to select a frail elderly population? A comparison of three working definitions. J Clin Epidemiol 1999; 52:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/8\">",
"      Cigolle CT, Ofstedal MB, Tian Z, Blaum CS. Comparing models of frailty: the Health and Retirement Study. J Am Geriatr Soc 2009; 57:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/9\">",
"      Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc 2010; 58:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/10\">",
"      Newman AB, Gottdiener JS, Mcburnie MA, et al. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci 2001; 56:M158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/11\">",
"      Walston J. Frailty--the search for underlying causes. Sci Aging Knowledge Environ 2004; 2004:pe4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/12\">",
"      Avila-Funes JA, Amieva H, Barberger-Gateau P, et al. Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. J Am Geriatr Soc 2009; 57:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/13\">",
"      Boyle PA, Buchman AS, Wilson RS, et al. Physical frailty is associated with incident mild cognitive impairment in community-based older persons. J Am Geriatr Soc 2010; 58:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/14\">",
"      Ensrud KE, Ewing SK, Taylor BC, et al. Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med 2008; 168:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/15\">",
"      Ensrud KE, Ewing SK, Cawthon PM, et al. A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc 2009; 57:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/16\">",
"      Kiely DK, Cupples LA, Lipsitz LA. Validation and comparison of two frailty indexes: The MOBILIZE Boston Study. J Am Geriatr Soc 2009; 57:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/17\">",
"      Rothman MD, Leo-Summers L, Gill TM. Prognostic significance of potential frailty criteria. J Am Geriatr Soc 2008; 56:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/18\">",
"      Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 2010; 210:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/19\">",
"      Romero-Ortuno R, Walsh CD, Lawlor BA, Kenny RA. A frailty instrument for primary care: findings from the Survey of Health, Ageing and Retirement in Europe (SHARE). BMC Geriatr 2010; 10:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/20\">",
"      Rockwood K, Andrew M, Mitnitski A. A comparison of two approaches to measuring frailty in elderly people. J Gerontol A Biol Sci Med Sci 2007; 62:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/21\">",
"      Yao X, Hamilton RG, Weng NP, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine 2011; 29:5015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/22\">",
"      Garonzik-Wang JM, Govindan P, Grinnan JW, et al. Frailty and delayed graft function in kidney transplant recipients. Arch Surg 2012; 147:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/23\">",
"      Bandeen-Roche K, Xue QL, Ferrucci L, et al. Phenotype of frailty: characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci 2006; 61:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/24\">",
"      Ahmed N, Mandel R, Fain MJ. Frailty: an emerging geriatric syndrome. Am J Med 2007; 120:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/25\">",
"      Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc 2012; 60:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/26\">",
"      Woods NF, LaCroix AZ, Gray SL, et al. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc 2005; 53:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/27\">",
"      Cawthon PM, Marshall LM, Michael Y, et al. Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc 2007; 55:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/28\">",
"      Evenhuis HM, Hermans H, Hilgenkamp TI, et al. Frailty and disability in older adults with intellectual disabilities: results from the healthy ageing and intellectual disability study. J Am Geriatr Soc 2012; 60:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/29\">",
"      Lakey SL, LaCroix AZ, Gray SL, et al. Antidepressant use, depressive symptoms, and incident frailty in women aged 65 and older from the Women's Health Initiative Observational Study. J Am Geriatr Soc 2012; 60:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/30\">",
"      Leng SX, Cappola AR, Andersen RE, et al. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res 2004; 16:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/31\">",
"      Valenti G, Denti L, Maggio M, et al. Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2004; 59:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/32\">",
"      Wang H, Casaburi R, Taylor WE, et al. Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I receptor is decreased in sedentary chronic hemodialysis patients. Kidney Int 2005; 68:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/33\">",
"      Schaap LA, Pluijm SM, Deeg DJ, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 2009; 64:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/34\">",
"      Morley JE, Baumgartner RN, Roubenoff R, et al. Sarcopenia. J Lab Clin Med 2001; 137:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/35\">",
"      Poehlman ET, Toth MJ, Fishman PS, et al. Sarcopenia in aging humans: the impact of menopause and disease. J Gerontol A Biol Sci Med Sci 1995; 50 Spec No:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/36\">",
"      O'Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: The Massachusetts Male Aging Study (1987-2004). Exp Gerontol 2004; 39:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/37\">",
"      Travison TG, Nguyen AH, Naganathan V, et al. Changes in reproductive hormone concentrations predict the prevalence and progression of the frailty syndrome in older men: the concord health and ageing in men project. J Clin Endocrinol Metab 2011; 96:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/38\">",
"      Mohr BA, Bhasin S, Kupelian V, et al. Testosterone, sex hormone-binding globulin, and frailty in older men. J Am Geriatr Soc 2007; 55:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/39\">",
"      Nass R, Thorner MO. Impact of the GH-cortisol ratio on the age-dependent changes in body composition. Growth Horm IGF Res 2002; 12:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/40\">",
"      Lanfranco F, Gianotti L, Giordano R, et al. Ageing, growth hormone and physical performance. J Endocrinol Invest 2003; 26:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/41\">",
"      Cappola AR, Xue QL, Ferrucci L, et al. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 2003; 88:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/42\">",
"      Schmidt M, Naumann H, Weidler C, et al. Inflammation and sex hormone metabolism. Ann N Y Acad Sci 2006; 1069:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/43\">",
"      Varadhan R, Walston J, Cappola AR, et al. Higher levels and blunted diurnal variation of cortisol in frail older women. J Gerontol A Biol Sci Med Sci 2008; 63:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/44\">",
"      Puts MT, Visser M, Twisk JW, et al. Endocrine and inflammatory markers as predictors of frailty. Clin Endocrinol (Oxf) 2005; 63:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/45\">",
"      Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol Aspects Med 2005; 26:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/46\">",
"      Walston J, McBurnie MA, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med 2002; 162:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/47\">",
"      Leng SX, Xue QL, Tian J, et al. Associations of neutrophil and monocyte counts with frailty in community-dwelling disabled older women: results from the Women's Health and Aging Studies I. Exp Gerontol 2009; 44:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/48\">",
"      Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000; 51:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/49\">",
"      Ershler WB. Biological interactions of aging and anemia: a focus on cytokines. J Am Geriatr Soc 2003; 51:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/50\">",
"      Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc 2002; 50:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/51\">",
"      Varadhan R, Chaves PH, Lipsitz LA, et al. Frailty and impaired cardiac autonomic control: new insights from principal components aggregation of traditional heart rate variability indices. J Gerontol A Biol Sci Med Sci 2009; 64:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/52\">",
"      Burks TN, Andres-Mateos E, Marx R, et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 2011; 3:82ra37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/53\">",
"      Daley MJ, Spinks WL. Exercise, mobility and aging. Sports Med 2000; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/54\">",
"      Spirduso WW, Cronin DL. Exercise dose-response effects on quality of life and independent living in older adults. Med Sci Sports Exerc 2001; 33:S598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/55\">",
"      Keysor JJ. Does late-life physical activity or exercise prevent or minimize disablement? A critical review of the scientific evidence. Am J Prev Med 2003; 25:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/56\">",
"      Province MA, Hadley EC, Hornbrook MC, et al. The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FICSIT Trials. Frailty and Injuries: Cooperative Studies of Intervention Techniques. JAMA 1995; 273:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/57\">",
"      Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011; 364:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/58\">",
"      Roubenoff R. Sarcopenia: a major modifiable cause of frailty in the elderly. J Nutr Health Aging 2000; 4:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/59\">",
"      Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/60\">",
"      Hunter GR, McCarthy JP, Bamman MM. Effects of resistance training on older adults. Sports Med 2004; 34:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/61\">",
"      Miller ME, Rejeski WJ, Reboussin BA, et al. Physical activity, functional limitations, and disability in older adults. J Am Geriatr Soc 2000; 48:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/62\">",
"      Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science 1997; 278:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/63\">",
"      Tenover JS. Androgen replacement therapy to reverse and/or prevent age-associated sarcopenia in men. Baillieres Clin Endocrinol Metab 1998; 12:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/64\">",
"      Lamberts SW. The somatopause: to treat or not to treat? Horm Res 2000; 53 Suppl 3:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/65\">",
"      Morley JE, Kim MJ, Haren MT. Frailty and hormones. Rev Endocr Metab Disord 2005; 6:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/66\">",
"      Ensrud KE, Blackwell TL, Cauley JA, et al. Circulating 25-hydroxyvitamin D levels and frailty in older men: the osteoporotic fractures in men study. J Am Geriatr Soc 2011; 59:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/67\">",
"      Ko FC. The clinical care of frail, older adults. Clin Geriatr Med 2011; 27:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/68\">",
"      Ganz DA, Fung CH, Sinsky CA, et al. Key elements of high-quality primary care for vulnerable elders. J Gen Intern Med 2008; 23:2018.",
"     </a>",
"    </li>",
"    <li>",
"     Urdangarin CF. Comprehensive Geriatric Assessment and Management. In: Assessing Older Persons, Kane RL, Kane RA (Eds), Oxford University Press, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/70\">",
"      Eng C, Pedulla J, Eleazer GP, et al. Program of All-inclusive Care for the Elderly (PACE): an innovative model of integrated geriatric care and financing. J Am Geriatr Soc 1997; 45:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/71\">",
"      Mukamel DB, Peterson DR, Temkin-Greener H, et al. Program characteristics and enrollees' outcomes in the Program of All-Inclusive Care for the Elderly (PACE). Milbank Q 2007; 85:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/72\">",
"      Palmer RM, Counsell S, Landefeld CS. Clinical intervention trials: the ACE unit. Clin Geriatr Med 1998; 14:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/73\">",
"      Sager MA, Franke T, Inouye SK, et al. Functional outcomes of acute medical illness and hospitalization in older persons. Arch Intern Med 1996; 156:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/74\">",
"      Gill TM, Allore HG, Gahbauer EA, Murphy TE. Change in disability after hospitalization or restricted activity in older persons. JAMA 2010; 304:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/75\">",
"      Counsell SR, Holder CM, Liebenauer LL, et al. Effects of a multicomponent intervention on functional outcomes and process of care in hospitalized older patients: a randomized controlled trial of Acute Care for Elders (ACE) in a community hospital. J Am Geriatr Soc 2000; 48:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/76\">",
"      Goldberg TH, Chavin SI. Preventive medicine and screening in older adults. J Am Geriatr Soc 1997; 45:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28792/abstract/77\">",
"      Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285:2750.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3010 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28792=[""].join("\n");
var outline_f28_7_28792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cardiovascular Health Study index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Study of Osteoporotic Fractures index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1300407706\">",
"      Rockwood frailty index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1300407734\">",
"      FRAILTY AS A RISK ASSESSMENT TOOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endocrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inflammation and the immune system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1300407959\">",
"      Other stress response and metabolic systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Exercise and nutrition interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hormonal/supplemental interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MODEL SYSTEMS OF CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Comprehensive geriatric assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Outpatient PACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hospital care and ACE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TAILORING INDIVIDUAL CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/3010\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3010|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/22/7535\" title=\"figure 1\">",
"      Pathway frailty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/34/29230\" title=\"figure 2\">",
"      Spectrum of frailty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43624?source=related_link\">",
"      Comprehensive geriatric assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12650?source=related_link\">",
"      Endocrine changes with aging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34215?source=related_link\">",
"      Failure to thrive in elderly adults: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42455?source=related_link\">",
"      Failure to thrive in elderly adults: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9161?source=related_link\">",
"      Physical activity and exercise in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8393?source=related_link\">",
"      Prevention of falls and complications of falls in community-dwelling older persons",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_7_28793="Etiology and clinical features of bladder dysfunction in children";
var content_f28_7_28793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and clinical features of bladder dysfunction in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/7/28793/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28793/contributors\">",
"     Kenneth G Nepple, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28793/contributors\">",
"     Christopher S Cooper, MD, FACS, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/7/28793/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28793/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/7/28793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28793/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/7/28793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder dysfunction, also referred to as voiding dysfunction, is a general term to describe abnormalities in either the filling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emptying of the bladder. It is a common problem in children and constitutes up to 40 percent of pediatric urology clinic visits [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/1\">",
"     1",
"    </a>",
"    ]. In some children, bladder dysfunction is a component of bowel and bladder dysfunction, previously been referred to as dysfunction elimination, which involves abnormalities in both bladder and bowel emptying.",
"   </p>",
"   <p>",
"    The etiology and clinical features of non-neurologic bladder dysfunction in children will be reviewed here. The evaluation of non-neurologic bladder dysfunction in children is discussed separately. The clinical features, evaluation, and management of children with bladder dysfunction due to myelomeningocele also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=see_link\">",
"     \"Evaluation and diagnosis of bladder dysfunction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15288?source=see_link\">",
"     \"Urinary tract complications of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS OF SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Children's Continence Society (ICCS), a global multidisciplinary organization of clinicians involved in the care of children with lower urinary tract dysfunction, developed standardized definitions for bladder dysfunction symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/2\">",
"     2",
"    </a>",
"    ]. We will use the following ICCS definitions, which apply only to children who are five or more years of age, unless specifically noted otherwise.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Daytime frequency &ndash; Increased daytime frequency is defined as voiding eight or more times during waking hours, whereas decreased daytime frequency is defined as three or fewer voids. The term pollakiuria is also used to define abnormally frequent small voids in a previously toilet trained child with no evidence of polyuria or urinary tract infection.",
"     </li>",
"     <li>",
"      Incontinence &ndash; Incontinence is defined as uncontrolled leakage of urine, which can be continuous or intermittent.",
"     </li>",
"     <li>",
"      Urgency &ndash; Urgency is defined as the sudden and unexpected experience of an immediate need to void.",
"     </li>",
"     <li>",
"      Nocturia &ndash; Nocturia is defined as awakening to void at night.",
"     </li>",
"     <li>",
"      Hesitancy &ndash; Hesitancy is defined as difficulty in the initiation of voiding or if a child must wait a considerable amount of time before voiding starts. This term can be applied to children who have achieved bladder control regardless of age.",
"     </li>",
"     <li>",
"      Straining &ndash; Straining is defined as the application of abdominal pressure (Valsalva maneuver) by the child to initiate and maintain voiding, and may be a pertinent finding in all age groups.",
"     </li>",
"     <li>",
"      Weak stream &ndash; A weak stream is defined as the observed ejection of urine with a weak force and may be a pertinent finding in all age groups.",
"     </li>",
"     <li>",
"      Intermittent stream &ndash; Intermittency of voiding is defined as a voiding stream of urine that occurs in several discrete bursts rather than the normal continuous stream. It is a normal physiologic pattern in children three years of age or younger.",
"     </li>",
"     <li>",
"      Holding maneuvers &ndash; Holding maneuvers are observed behavior used to either postpone voiding or suppress urgency. Common maneuvers include standing on tiptoe, forcefully crossing the legs, or squatting with a hand or heel pressed into the perineum (",
"      <a class=\"graphic graphic_picture graphicRef75506 \" href=\"UTD.htm?10/12/10440\">",
"       picture 1",
"      </a>",
"      ) (Vincent's curtsy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/3\">",
"       3",
"      </a>",
"      ]). These may be observed in children who have achieved bladder control regardless of age.",
"     </li>",
"     <li>",
"      Post-micturition dribbling &ndash; Post-micturition dribbling describes involuntary urine leakage immediately after completion of voiding in children who have achieved bladder control regardless of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMAL VOIDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two functional roles of the bladder are storage and elimination of urine. The normal development of bladder control evolves from involuntary bladder emptying (incontinence) during infancy to daytime urinary continence, which normally occurs by four years of age, and finally successful day and night continence generally achieved by five or seven years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/4\">",
"     4",
"    </a>",
"    ]. Urinary continence is generally achieved after successful daytime and nighttime bowel continence.",
"   </p>",
"   <p>",
"    In one study of 1192 children from the United States, the reported mean age of daytime urinary control was 2.4 &plusmn; 0.6 years (range 0.75 to 5 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/5\">",
"     5",
"    </a>",
"    ]. By 10 years of age, 85 percent of children obtained nighttime urinary continence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37592?source=see_link\">",
"     \"Toilet training\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40281?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology and evaluation of nocturnal enuresis in children\", section on 'Epidemiology and natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a large prospective cohort study of almost 11,000 children from England, the prevalence rate of urinary daytime incontinence declined from 15.5 to 4.9 percent between the ages of 4.5 to 9.5 years. Daytime incontinence was more common in girls in this cohort; however, the urinary incontinence decreased at a similar rate between girls (11 to 3.2 percent) and boys (6 to 3.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary continence is dependent upon a complex interrelationship between autonomic and somatic nerves, which are integrated at various sites in the spinal cord, brainstem, midbrain, and higher cortical centers (",
"    <a class=\"graphic graphic_figure graphicRef65433 \" href=\"UTD.htm?10/55/11125\">",
"     figure 1",
"    </a>",
"    ). The normal coordination of the central and peripheral nervous system network permits the filling of the bladder and urine storage at low pressure with high outlet resistance, and voiding with low outlet resistance and sustained detrusor (bladder wall muscle) contraction.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Filling phase &ndash; To eliminate bladder contraction during the filling phase, activation of the sympathetic nervous system beta receptors of the bladder fundus results in detrusor muscle relaxation. Activation of sympathetic alpha receptors at the bladder neck result in bladder neck contraction and increased bladder outlet resistance. Stimulation of the pudendal motor neurons contracts the external urinary sphincter closing the bladder outlet and ensuring continence during the filling phase. The normal bladder is highly compliant and allows the storage of urine at low pressures. One study reported that over 95 percent of children have bladder storage pressures of &lt;30 cm H2O at full capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/8\">",
"       8",
"      </a>",
"      ]. If the bladder stores urine at high pressures (&gt;40 cm H2O), kidney injury may occur [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/9\">",
"       9",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"     <li>",
"      Voiding phase &ndash; As the bladder fills, stretching activates mechanoreceptors, which send an ascending signal through the spinal cord to the pontine micturition center in the brainstem. A descending signal from the pontine micturition through the spinal cord results in inhibition of the pudendal motor neurons, which relaxes the external urinary sphincter, stimulation of the parasympathetic outflow via the pelvic splanchnic nerves resulting in detrusor muscle contraction, and inhibition of the sympathetic nervous system through the hypogastric nerves, which relaxes the bladder neck. Input from the higher cerebral centers can modify the function of the pontine micturition center. The normal infant voids approximately 20 times per day, which results in small voided volumes and incomplete bladder emptying [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/10\">",
"       10",
"      </a>",
"      ]. Infantile bladder function had been thought to be due to a primarily immature state of filling and emptying by spinal cord reflex without volitional cortical control. However, some element of cortical control in infants appears to be present as supported by the observation that infants void while awake or during arousal from sleep and never during the quiet sleep phase [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/11\">",
"       11",
"      </a>",
"      ]. Thus, it is suggested that the development of voluntary urinary control is a learned modification of the already preexisting integrated network between the peripheral and central nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Development of bladder control is a progressive maturation process whereby the child first becomes aware of bladder filling, subsequently develops the ability to suppress detrusor contractions voluntarily, and finally learns to coordinate sphincter and detrusor function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/4\">",
"     4",
"    </a>",
"    ]. These skills usually are achieved, at least during the day, by approximately 4 years of age. Nighttime bladder control can be achieved months to years after daytime control, but is not considered abnormal until after 5 to 7 years of age. As voluntary bladder control matures, bladder capacity also increases and voiding frequency decreases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder dysfunction results from disruptions of the normal voiding process by any alteration of the innervation of the bladder or external sphincter, bladder compliance or volume capacity, detrusor muscle function, or structure of the bladder or bladder outlet. These include neurogenic, anatomic, or functional causes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurogenic causes &ndash; Neurogenic causes of bladder dysfunction disrupt the innervation of the bladder or external sphincter. Neurogenic causes are due to either congenital anomalies, such as myelomeningocele, or trauma to the central nervous system (eg, spinal cord injury). Any child with a suspected neurologic abnormality should be evaluated for occult neurologic lesion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15288?source=see_link\">",
"       \"Urinary tract complications of myelomeningocele (spina bifida)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anatomic causes &ndash; Children with an anatomic abnormality generally have a history of never gaining urinary control because the anatomic defect either bypasses the bladder outlet, such as ectopic ureter with insertion distal to the bladder neck (",
"      <a class=\"graphic graphic_figure graphicRef78218 \" href=\"UTD.htm?27/9/27798\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef65413 \" href=\"UTD.htm?41/1/42002\">",
"       figure 3",
"      </a>",
"      ), or there is obstruction of the bladder outlet (eg, posterior urethral valves). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39989?source=see_link\">",
"       \"Ectopic ureter\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Functional causes &ndash; Functional refers to idiopathic bladder dysfunction with no known anatomic or neurologic cause. Proposed theories regarding the pathogenesis of functional bladder dysfunction include maturation delay, prolongation of infantile bladder behavior, or abnormal acquired toilet training habits [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/2,13,14\">",
"       2,13,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DEFINITION OF BLADDER DYSFUNCTION DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Children's Continence Society (ICCS) has developed standardized definitions of several bladder dysfunction conditions based upon symptom complex and urodynamic tests. The goal of the ICCS classification is to use a set of uniform definitions to avoid the widespread use of different definitions for the same conditions that leads to an inability to compare studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions of symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The ICCS classification defines pediatric urinary incontinence into two major categories [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nocturnal enuresis or nighttime incontinence &ndash; Monosymptomatic nocturnal enuresis accounts for 80 percent of children with enuresis and is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40281?source=see_link\">",
"       \"Etiology and evaluation of nocturnal enuresis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7178?source=see_link\">",
"       \"Management of nocturnal enuresis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Daytime urinary incontinence disorders &ndash; These disorders encompass a variety of conditions that are generally applied to children at least five years of age with constant or daytime intermittent urinary leakage and are discussed in the next section.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DAYTIME URINARY INCONTINENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 20 percent of four to six year-old children experience occasional daytime wetting and 3 percent will have wetting accidents two or more times per week [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of daytime urinary incontinence, defined as a wetting accident at least once every two weeks, decreases with increasing age as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Five to six year-old children &ndash; 10 percent",
"     </li>",
"     <li>",
"      Six to 12 year-old children &ndash; 5 percent",
"     </li>",
"     <li>",
"      12 to 18 year-old children &ndash; 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one survey of primary school children in Australia with a mean age of 7.3 years and a response rate of 35 percent, 17 percent of reporting parents noted an episode of urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/17\">",
"     17",
"    </a>",
"    ]. The urinary incontinence was described as being very mild (urine spots on underwear), mild (damp underclothes and pants), moderate (noticeable seepage on outer clothing), and severe (wet puddle on floor or seat) in 64, 15, 12, and 10 percent of cases, respectively. Risk factors for urinary incontinence included female gender and a history of nocturnal enuresis, urinary tract infection or encopresis.",
"   </p>",
"   <p>",
"    Daytime urinary incontinence can cause major stress in school-age children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and negatively impact upon a child's self-esteem [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, it is desirable to identify and treat children with daytime urinary incontinence as early as possible.",
"   </p>",
"   <p>",
"    As defined by the ICCS, the following conditions and their underlying abnormalities of bladder function result in daytime urinary incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overactive bladder &ndash; Abnormal detrusor (bladder) contractions during filling.",
"     </li>",
"     <li>",
"      Voiding postponement and underactive bladder &ndash; Voiding postponement occurs in children who learn to habitually postpone micturition, resulting in a low frequency of voiding. Over time, some children with voiding postponement will develop an underactive bladder with weak or absent detrusor contraction.",
"     </li>",
"     <li>",
"      Dysfunctional voiding &ndash; Dysfunctional voiding is defined as detrusor contractions during voiding against a closed external urinary sphincter. This occurs in both children with a known neurologic lesion, referred to as detrusor urethral sphincter dyssynergy, or without a known neurologic lesion, referred to as non-neurogenic dysfunctional voiding.",
"     </li>",
"     <li>",
"      Other conditions &ndash; Other miscellaneous disorders that result in daytime urinary incontinence include giggle incontinence, vaginal voiding, and primary bladder neck dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be recognized that these groupings are not fully evidence based and did not include anatomical causes. The groupings are based upon the opinions of experts in the field of pediatric bladder dysfunction and there may be overlap between these conditions. In addition, changes in symptoms can evolve over time so that a single child may have components of different conditions. As an example, a child may start with an overactive bladder with urge incontinence and develop voiding postponement resulting in an underactive bladder. As new data emerge, future modifications of these conditions will be performed by the board of the ICCS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation and diagnosis of these conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=see_link\">",
"     \"Evaluation and diagnosis of bladder dysfunction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Overactive bladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overactive bladder is defined as abnormal bladder contraction during the filling phase and is detected by urodynamic evaluation. It is the second most common bladder dysfunction disorder following nocturnal enuresis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hallmark symptom of this disorder is urgency, and a clinical diagnosis can be made if urgency is present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/2\">",
"     2",
"    </a>",
"    ]. Incontinence and increased frequency are also common features of an overactive bladder. Holding maneuvers, such as Vincent's curtsy (squatting position with the legs crossed to prevent micturition or leaking), are often observed in affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of overactive bladder decreases with increasing age as illustrated in a study of the micturition habits of 1034 Swedish students evaluated twice; once when entering school and once during adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At seven years of age, 21 percent of girls and 18 percent of boys had moderate to severe urinary urgency. Daytime wetting occurred in 6 and 4 percent of girls and boys, respectively.",
"     </li>",
"     <li>",
"      At 17 years of age, 6 percent of girls and 1 percent of boys reported urgency, daytime incontinence, emptying difficulties, or enuresis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were reported from a cross-sectional survey of 19,240 Korean school children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/24\">",
"     24",
"    </a>",
"    ]. The overall incidence of overactive bladder defined as urgency with or without incontinence was 17 percent. The rate declined with increasing age with the highest incidence in five year-old children of 23 percent and the lowest in 13 year-old patients of 12 percent. Children with symptoms of overactive bladder compare to those without symptoms were more likely to have nocturnal enuresis, constipation, fecal incontinence, a history of urinary tract infection, delayed bladder control, and poor toilet facilities. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Associated conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Voiding postponement and underactive bladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Voiding postponement occurs in children who habitually postpone micturition, often in specific settings (eg, school). These children commonly have behavioral issues or have a psychological comorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Associated conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children with voiding postponement will utilize holding maneuvers to prevent voiding. These children generally have a low voiding frequency with long time intervals between voids that result in increasing bladder capacity over time.",
"   </p>",
"   <p>",
"    With overdistension of the bladder, the detrusor muscle becomes overstretched and hypoactive leading to a weak or absent contraction referred to as an underactive bladder, which was formerly called \"lazy bladder syndrome\" or myogenic failure. Children with underactive bladder will use a Valsalva maneuver to increase abdominal pressure (ie, straining) to aid in bladder emptying. However, despite these efforts, large-volume post-void residuals with overflow incontinence are common in these children. Urodynamic evaluation will demonstrate a large-capacity but compliant bladder and an interrupted urinary flow pattern is often observed.",
"   </p>",
"   <p>",
"    Children with underactive bladder are at increased risk for urinary tract infection because of post-void residuals. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Urinary tract infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Underactive bladder is seen in about 7 percent of children with dysfunctional voiding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/25\">",
"     25",
"    </a>",
"    ]. In this group of children, there is a predominance in females with a female to male ratio of 5 to 1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dysfunctional voiding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunctional voiding has been used interchangeably with bladder dysfunction as a general term to describe abnormalities of bladder function. However, the ICCS has reserved dysfunctional voiding to describe the inability to relax the urethral sphincter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pelvic floor musculature during voiding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detrusor urethral sphincter dyssynergy is defined as dysfunctional voiding in children with a known neurologic lesion. Urinary incontinence due to spinal cord malformations (eg, myelomeningocele) or acquired spinal cord injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15288?source=see_link\">",
"     \"Urinary tract complications of myelomeningocele (spina bifida)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H8#H8\">",
"     \"Chronic complications of spinal cord injury\", section on 'Urinary complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dysfunctional voiding in children without a known neurologic lesion is defined as non-neurogenic dysfunctional voiding. In these children, urodynamic studies demonstrate the abnormal contraction of the sphincter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pelvic floor musculature during voiding. Urinary flow is interrupted, producing a staccato pattern and a prolonged voiding time.",
"   </p>",
"   <p>",
"    Non-neurogenic dysfunctional voiding, also referred to as Hinman-Allen syndrome, is the most severe form of bladder dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The contraction of the sphincter during voiding and overactivity of the detrusor muscle can lead to high voiding pressure, bladder decompensation, and a predisposition for infection and renal damage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In some cases, hydronephrosis may be observed when radiologic imaging is performed.",
"   </p>",
"   <p>",
"    Patients with non-neurogenic bladder dysfunction are more likely to have constipation and, in more severe cases, encopresis and fecal soiling (ie, bowel and bladder dysfunction).",
"   </p>",
"   <p>",
"    Children with this disorder are at increased risk for urinary tract infection (UTI) and vesicoureteral reflux (VUR). VUR is thought to be due to the increased intravesical pressure generated during voiding against the closed sphincter. In more severe cases, imaging studies demonstrate hydronephrosis due to severe VUR, and trabeculated bladder due to bladder wall hypertrophy. Incomplete emptying is common and predisposes the child to an UTI. Renal scarring has also been reported as a result of renal injury in severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other miscellaneous disorders that result in daytime urinary incontinence include giggle incontinence, vaginal voiding, and primary bladder neck dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Giggle incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giggle incontinence, a rare syndrome, refers to urine leakage that occurs only with laughter [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/2\">",
"     2",
"    </a>",
"    ]. Children with giggle incontinence have normal bladder function when the child is not laughing and should be differentiated from urinary leakage with laughter in children who have persistent voiding symptoms when they are not laughing. It occurs almost exclusively in girls and is characterized by large-volume voids.",
"   </p>",
"   <p>",
"    Although the etiology of giggle incontinence is unclear, one theory suggests that this disorder is mediated by the central nervous system. The proposed mechanism is similar to that of cataplexy, in which an emotional event causes muscle hypotonia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of this condition is not well studied. Some experts in the field advocate the use of anticholinergics based upon the assumption that incontinence is related to detrusor instability [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/30\">",
"     30",
"    </a>",
"    ]. Small case series report that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    was effective in the prevention of these events suggesting a central nervous system etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In one small case series, biofeedback was effective in nine patients with giggle incontinence either refractory to medications or whose parents refused pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Vaginal voiding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal voiding or vaginal reflux of urine, is leakage of urine in toilet-trained girls when they stand up after voiding, and is a common cause of daytime urinary leakage in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/34\">",
"     34",
"    </a>",
"    ]. This is due to urine being temporarily trapped in the vagina during micturition. It occurs particularly in girls who urinate with their legs too closely approximated to permit free egress of urine. It is a pattern that can be seen during voiding cystourethrography with refluxing urine appearing within the vaginal vault during voiding.",
"   </p>",
"   <p>",
"    Girls with this condition may also have irritation of the labia and complain of dysuria as the urine passes over the irritated skin.",
"   </p>",
"   <p>",
"    Treatment is based upon changing the voiding habits of the child by emphasizing wide abduction of the legs and a forward leaning posture to reduce the likelihood of vaginal reflux of urine. Other helpful tips include sitting backwards on the toilet so that the legs need to straddle the toilet or manually spreading the labia majora while voiding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Primary neck bladder dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary neck bladder dysfunction is defined as delayed or incomplete opening of the bladder neck during voiding in patients with normally functioning sphincter and pelvic floor muscles. It may be underdiagnosed in children and, in a pediatric urologic center, it is reported to represent up to 15 percent of children with persistent voiding symptoms despite conventional treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/25\">",
"     25",
"    </a>",
"    ]. Symptoms include hesitancy, frequency, urgency, weak urinary stream, pelvic pain or discomfort during voiding, sense of incomplete emptying, and occasional nocturnal enuresis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of this condition is not well studied. Alpha-blockers have been reported to be effective and well-tolerated in the treatment of this disorder in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ASSOCIATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following comorbid conditions are associated with bladder dysfunction in children:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urinary tract infection",
"     </li>",
"     <li>",
"      Vesicoureteral reflux",
"     </li>",
"     <li>",
"      Constipation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there appears to be an increased frequency of behavioral and neurodevelopment issues in children with bladder dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a clear association between bladder dysfunction and urinary tract infection (UTI) has been established, it is unclear whether there is a causal relationship. It has been theorized that a UTI may precipitate the development of bladder dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/12\">",
"     12",
"    </a>",
"    ]; however, data based upon case series support the supposition that bladder dysfunction predisposes children to recurrent UTI and renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In particular, the risk of bladder colonization and UTI is increased in children with incomplete bladder emptying due to dysfunctional voiding or underactive bladder, or in those with primary neck bladder dysfunction with opening of the bladder neck during contraction.",
"   </p>",
"   <p>",
"    Several studies have demonstrated the association between bladder dysfunction and recurrent UTIs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of children of 1000 children selected for video-urodynamic studies, the risk of UTI was only increased in girls [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/38\">",
"       38",
"      </a>",
"      ]. One-third of the girls with dysfunctional voiding and one-half of girls with underactive bladder had a history of UTI.",
"     </li>",
"     <li>",
"      In a study of 340 children (greater than one year of age) who had overactive bladder confirmed by urodynamic testing, 46 percent had vesicoureteral reflux (VUR) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/40\">",
"       40",
"      </a>",
"      ]. Mean age in the refluxing group was lower than the nonrefluxing group (6.7 versus 7.6 years). Median maximum filling pressure was higher in patients with VUR compared to those without VUR (40 versus 34 cm H2O).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these results, urine analysis and culture should be performed in all children with bladder dysfunction to screen for UTIs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vesicoureteral reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon several large case series, an association between vesicoureteral reflux (VUR) and bladder dysfunction has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/38,41,42\">",
"     38,41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 143 children with VUR, 43 percent were noted to have dysfunctional elimination syndrome (DES) with both abnormal bowel and bladder function [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two studies, 16 to 20 percent of children with bladder dysfunction who underwent video-urodynamic testing had VUR [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/38,41\">",
"       38,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 340 children (greater than one year of age) who had overactive bladder confirmed by urodynamic testing, 46 percent had VUR [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Voiding against a closed sphincter can increase bladder pressure and may contribute to the development and persistence of VUR [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. It has also been theorized that bladder wall thickening (detrusor hypertrophy) changes the closure mechanism at the ureterovesical junction.",
"   </p>",
"   <p>",
"    In one study, the presence of DES decreased the chance of spontaneous VUR resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/45\">",
"     45",
"    </a>",
"    ]. If VUR resolution occurs, the time for resolution increases by 1.6 years in those with DES compared to those without DES [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link&amp;anchor=H3#H3\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\", section on 'Primary VUR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cost of VUR treatment increases when bladder dysfunction is present because of the higher incidence of UTI, longer time for VUR resolution, and increased failure rate of surgical correction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of bladder dysfunction, particularly overactive bladder, has been shown to improve the spontaneous VUR resolution rate, suggesting an etiologic component for overactive bladder in the genesis of reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/42,47,48\">",
"     42,47,48",
"    </a>",
"    ]. However, one study of high grade reflux in infants with bladder dysfunction treated with intermittent catheterization reported a persistent low rate of resolution during a four-year follow-up period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bladder dysfunction is associated with a higher failure rate of surgical correction for VUR either by endoscopic repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/50\">",
"     50",
"    </a>",
"    ] or open surgical reimplantation, particularly if there is detrusor-sphincter incoordination [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Patients with DES also have a lower rate of successful open surgical reimplantation. Overactive bladder does not appear to affect the success rate of open surgical reimplantation but postoperative infection in these children is more common [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic renal insufficiency has been reported in a small case series of children with bladder dysfunction, recurrent UTIs, and VUR [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Constipation and dysfunctional elimination syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorectal and lower urinary tract function are interrelated. As a result, constipation is often associated with bladder dysfunction with a reported frequency that ranges from 30 to 88 percent of children with bladder dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/41,55\">",
"     41,55",
"    </a>",
"    ]. This relationship between abnormal bowel and bladder function is referred to as the dysfunctional elimination syndrome (DES) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/42,56,57\">",
"     42,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the underlying mechanism is not fully understood, two theories have been proposed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first proposal suggests that rectal distention in the constipated child places direct pressure on the posterior bladder wall leading to detrusor overactivity or impaired bladder emptying [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/58,59\">",
"       58,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second proposal assumes that urethral and anal sphincter neural input is a single functional unit. Prolonged external anal sphincter contraction in the presence of a large amount of stool in the rectum leads to inappropriate pelvic floor muscle contraction and secondary detrusor-urinary sphincter dyssynergy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/60\">",
"       60",
"      </a>",
"      ]. Increased parasympathetic activity may also be present as a result of the colonic and rectal distention, which leads to detrusor contraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a review of 2759 children treated for VUR at a pediatric urology referral center, 36 percent of girls and 21 percent of boys with unilateral VUR had DES [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/61\">",
"     61",
"    </a>",
"    ]. Multivariate analysis demonstrated that DES was not independently associated with either UTI or VUR alone but was strongly associated with the combination of the two. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=see_link\">",
"     \"Constipation in children: Etiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Behavioral and neurodevelopmental issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional causes of bladder dysfunction are often believed to originate from behavioral issues arising from toilet training or personal stress. In some cases, there may be a mild maturational delay of the central nervous system that disrupts the ability of these children to gain true voluntary bladder control by five years of age. In others, voluntary holding with postponement of voiding is acquired and may be reflective of ongoing behavioral issues [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/62\">",
"     62",
"    </a>",
"    ], such as parent-child conflict. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37592?source=see_link&amp;anchor=H19#H19\">",
"     \"Toilet training\", section on 'Resistance or refusal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from case series support the association between attention deficit hyperactivity disorder (ADHD) and bladder dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. In one study, children with ADHD were more likely to report symptoms of incontinence, urgency, infrequent voiding, nocturnal enuresis, and dysuria than those without ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study from Germany, 141 children who were referred for evaluation of bladder dysfunction were assessed for behavioral problems and psychiatric comorbidity using a standardized parental questionnaire (Child Behavior Checklist) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/66\">",
"     66",
"    </a>",
"    ]. The patient group included children with only nocturnal enuresis (46 percent) and those with daytime incontinence (42 percent). In the overall group, 40 percent of patients were reported to have behavioral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychiatric problems. The highest rates were found in children with voiding postponement and the lowest in those with monosymptomatic nocturnal enuresis.",
"   </p>",
"   <p>",
"    Bladder dysfunction may partly be a behavioral or learned process that perpetuates itself when not treated. Limiting access to the bathroom or discouraging voiding in response to the urge to urinate in a child who has not developed complete cortical inhibition of voiding may alter normal bladder and sphincter function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/67\">",
"     67",
"    </a>",
"    ]. In part, this is due to a lack of awareness of teachers, school administrators, and parents of the significance of daytime incontinence as a marker for bladder dysfunction. In a survey of 467 teachers, only 16 percent of teachers suspected an underlying health problem when a child had daytime wetting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/68\">",
"     68",
"    </a>",
"    ]. Similar findings were reported in a survey of 1419 primary school children that demonstrated only 16 percent of children with daytime incontinence sought treatment, and only increased to 40 percent with daily wetting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28793/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children may also avoid the school bathroom due to the lack of privacy or sanitation resulting in voiding postponement. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Voiding postponement and underactive bladder'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/2/21538?source=see_link\">",
"       \"Patient information: Daytime wetting (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38193?source=see_link\">",
"       \"Patient information: Vesicoureteral reflux in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder dysfunction, defined as abnormalities in either filling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emptying the bladder, is a common problem in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bladder function normally evolves from involuntary bladder emptying (urinary incontinence) during infancy to voluntary control urinary continence generally achieved by five years of age. Urinary continence is dependent upon coordination of an interrelated network of autonomic and somatic nerves of the central and peripheral nervous systems (",
"      <a class=\"graphic graphic_figure graphicRef65433 \" href=\"UTD.htm?10/55/11125\">",
"       figure 1",
"      </a>",
"      ). Normal coordination results in bladder filling and urine storage at low pressure with high outlet resistance, and voiding with low outlet resistance and sustained detrusor (bladder wall muscle) contraction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Normal voiding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bladder dysfunction results from neurogenic, anatomic, or functional disruptions of the normal voiding process. Bladder dysfunction is divided in two major categories; continuous or daytime urinary incontinent disorders, and nocturnal enuresis or nighttime incontinence. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Definition of bladder dysfunction disorders'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40281?source=see_link\">",
"       \"Etiology and evaluation of nocturnal enuresis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Daytime urinary incontinent disorders include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Overactive bladder defined as abnormal detrusor (bladder wall muscle) contractions during bladder filling. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Overactive bladder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Voiding postponement is the postponement of micturition resulting in a low frequency rate of voiding and increased bladder capacity. Over time, some children will develop an underactive bladder with weak or absent detrusor contraction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Voiding postponement and underactive bladder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dysfunctional voiding, defined as detrusor contractions against a closed external urinary sphincter during voiding, occurs in both children with a known neurologic lesion (ie, detrusor urethral sphincter dyssynergy) or without a known neurologic lesion (ie, non-neurogenic dysfunctional voiding). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Dysfunctional voiding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other daytime urinary incontinent disorders include giggle incontinence, vaginal voiding, and primary bladder neck dysfunction. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comorbid conditions associated with bladder dysfunction include urinary tract infections, vesicoureteral reflux, and constipation. In addition, there appears to be an increase frequency of behavioral and neurodevelopment issues in children with bladder dysfunction. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Associated conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/1\">",
"      Farhat W, B&auml;gli DJ, Capolicchio G, et al. The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. J Urol 2000; 164:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/2\">",
"      Nev&eacute;us T, von Gontard A, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol 2006; 176:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/3\">",
"      Vincent SA. Postural control of urinary incontinence. The curtsy sign. Lancet 1966; 2:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/4\">",
"      Jansson UB, Hanson M, Sill&eacute;n U, Hellstr&ouml;m AL. Voiding pattern and acquisition of bladder control from birth to age 6 years--a longitudinal study. J Urol 2005; 174:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/5\">",
"      Bloom DA, Seeley WW, Ritchey ML, McGuire EJ. Toilet habits and continence in children: an opportunity sampling in search of normal parameters. J Urol 1993; 149:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/6\">",
"      Heron J, Joinson C, Croudace T, von Gontard A. Trajectories of daytime wetting and soiling in a United kingdom 4 to 9-year-old population birth cohort study. J Urol 2008; 179:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/7\">",
"      Swithinbank LV, Heron J, von Gontard A, Abrams P. The natural history of daytime urinary incontinence in children: a large British cohort. Acta Paediatr 2010; 99:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/8\">",
"      Houle AM, Gilmour RF, Churchill BM, et al. What volume can a child normally store in the bladder at a safe pressure? J Urol 1993; 149:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/9\">",
"      McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 1981; 126:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/10\">",
"      Holmdahl G, Hanson E, Hanson M, et al. Four-hour voiding observation in healthy infants. J Urol 1996; 156:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/11\">",
"      Yeung CK, Godley ML, Ho CK, et al. Some new insights into bladder function in infancy. Br J Urol 1995; 76:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/12\">",
"      Bauer SB. Special considerations of the overactive bladder in children. Urology 2002; 60:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/13\">",
"      Nijman RJ. Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children. Urology 2004; 63:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/14\">",
"      Greenfield SP. The overactive bladder in childhood. J Urol 2000; 163:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/15\">",
"      Sureshkumar P, Craig JC, Roy LP, Knight JF. Daytime urinary incontinence in primary school children: a population-based survey. J Pediatr 2000; 137:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/16\">",
"      Robson WL. Diurnal enuresis. Pediatr Rev 1997; 18:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/17\">",
"      Sureshkumar P, Jones M, Cumming R, Craig J. A population based study of 2,856 school-age children with urinary incontinence. J Urol 2009; 181:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/18\">",
"      Anderson GE, Jimerson SR, Whipple AD. Student Ratings of Stressful Experiences at Home and School: Loss of a Parent and Grade Retention as Superlative Stressors. Journal of Applied School Psychology 2005; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/19\">",
"      Ollendick TH, King NJ, Frary RB. Fears in children and adolescents: reliability and generalizability across gender, age and nationality. Behav Res Ther 1989; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/20\">",
"      H&auml;ggl&ouml;f B, Andr&eacute;n O, Bergstr&ouml;m E, et al. Self-esteem in children with nocturnal enuresis and urinary incontinence: improvement of self-esteem after treatment. Eur Urol 1998; 33 Suppl 3:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/21\">",
"      Hellerstein S, Zguta AA. Outcome of overactive bladder in children. Clin Pediatr (Phila) 2003; 42:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/22\">",
"      Hellstr&ouml;m A, Hanson E, Hansson S, et al. Micturition habits and incontinence at age 17--reinvestigation ofa cohort studied at age 7. Br J Urol 1995; 76:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/23\">",
"      Hellstr&ouml;m AL, Hanson E, Hansson S, et al. Micturition habits and incontinence in 7-year-old Swedish school entrants. Eur J Pediatr 1990; 149:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/24\">",
"      Chung JM, Lee SD, Kang DI, et al. Prevalence and associated factors of overactive bladder in Korean children 5-13 years old: a nationwide multicenter study. Urology 2009; 73:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/25\">",
"      Feldman AS, Bauer SB. Diagnosis and management of dysfunctional voiding. Curr Opin Pediatr 2006; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/26\">",
"      Hinman F, Baumann FW. Vesical and ureteral damage from voiding dysfunction in boys without neurologic or obstructive disease. J Urol 1973; 109:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/27\">",
"      Allen TD. The non-neurogenic neurogenic bladder. J Urol 1977; 117:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/28\">",
"      Jayanthi VR, Khoury AE, McLorie GA, Agarwal SK. The nonneurogenic neurogenic bladder of early infancy. J Urol 1997; 158:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/29\">",
"      Hinman F Jr. Nonneurogenic neurogenic bladder (the Hinman syndrome)--15 years later. J Urol 1986; 136:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/30\">",
"      Chandra M, Saharia R, Shi Q, Hill V. Giggle incontinence in children: a manifestation of detrusor instability. J Urol 2002; 168:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/31\">",
"      Sher PK, Reinberg Y. Successful treatment of giggle incontinence with methylphenidate. J Urol 1996; 156:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/32\">",
"      Berry AK, Zderic S, Carr M. Methylphenidate for giggle incontinence. J Urol 2009; 182:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/33\">",
"      Richardson I, Palmer LS. Successful treatment for giggle incontinence with biofeedback. J Urol 2009; 182:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/34\">",
"      Bernasconi M, Borsari A, Garzoni L, et al. Vaginal voiding: a common cause of daytime urinary leakage in girls. J Pediatr Adolesc Gynecol 2009; 22:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/35\">",
"      Grafstein NH, Combs AJ, Glassberg KI. Primary bladder neck dysfunction: an overlooked entity in children. Curr Urol Rep 2005; 6:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/36\">",
"      Donohoe JM, Combs AJ, Glassberg KI. Primary bladder neck dysfunction in children and adolescents II: results of treatment with alpha-adrenergic antagonists. J Urol 2005; 173:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/37\">",
"      Van Batavia JP, Combs AJ, Horowitz M, Glassberg KI. Primary bladder neck dysfunction in children and adolescents III: results of long-term alpha-blocker therapy. J Urol 2010; 183:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/38\">",
"      Hoebeke P, Van Laecke E, Van Camp C, et al. One thousand video-urodynamic studies in children with non-neurogenic bladder sphincter dysfunction. BJU Int 2001; 87:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/39\">",
"      Nijman RJ. Classification and treatment of functional incontinence in children. BJU Int 2000; 85 Suppl 3:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/40\">",
"      Ural Z, Ulman I, Avanoglu A. Bladder dynamics and vesicoureteral reflux: factors associated with idiopathic lower urinary tract dysfunction in children. J Urol 2008; 179:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/41\">",
"      Schulman SL, Quinn CK, Plachter N, Kodman-Jones C. Comprehensive management of dysfunctional voiding. Pediatrics 1999; 103:E31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/42\">",
"      Koff SA, Wagner TT, Jayanthi VR. The relationship among dysfunctional elimination syndromes, primary vesicoureteral reflux and urinary tract infections in children. J Urol 1998; 160:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/43\">",
"      Chandra M, Maddix H. Urodynamic dysfunction in infants with vesicoureteral reflux. J Pediatr 2000; 136:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/44\">",
"      Yeung CK, Godley ML, Dhillon HK, et al. Urodynamic patterns in infants with normal lower urinary tracts or primary vesico-ureteric reflux. Br J Urol 1998; 81:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/45\">",
"      Yeung CK, Sreedhar B, Sihoe JD, Sit FK. Renal and bladder functional status at diagnosis as predictive factors for the outcome of primary vesicoureteral reflux in children. J Urol 2006; 176:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/46\">",
"      Benoit RM, Wise BV, Naslund MJ, et al. The effect of dysfunctional voiding on the costs of treating vesicoureteral reflux: a computer model. J Urol 2002; 168:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/47\">",
"      Willemsen J, Nijman RJ. Vesicoureteral reflux and videourodynamic studies: results of a prospective study. Urology 2000; 55:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/48\">",
"      Homsy YL, Nsouli I, Hamburger B, et al. Effects of oxybutynin on vesicoureteral reflux in children. J Urol 1985; 134:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/49\">",
"      Sill&eacute;n U, Holmdahl G, Hellstr&ouml;m AL, et al. Treatment of bladder dysfunction and high grade vesicoureteral reflux does not influence the spontaneous resolution rate. J Urol 2007; 177:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/50\">",
"      Capozza N, Lais A, Matarazzo E, et al. Influence of voiding dysfunction on the outcome of endoscopic treatment for vesicoureteral reflux. J Urol 2002; 168:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/51\">",
"      Noe HN. The role of dysfunctional voiding in failure or complication of ureteral reimplantation for primary reflux. J Urol 1985; 134:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/52\">",
"      Nasrallah PF, Simon JW. Reflux and voiding abnormalities in children. Urology 1984; 24:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/53\">",
"      Barroso U Jr, Jednak R, Barthold JS, Gonz&aacute;lez R. Outcome of ureteral reimplantation in children with the urge syndrome. J Urol 2001; 166:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/54\">",
"      Varlam DE, Dippell J. Non-neurogenic bladder and chronic renal insufficiency in childhood. Pediatr Nephrol 1995; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/55\">",
"      O'Regan S, Yazbeck S, Hamberger B, Schick E. Constipation a commonly unrecognized cause of enuresis. Am J Dis Child 1986; 140:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/56\">",
"      Bower WF, Yip SK, Yeung CK. Dysfunctional elimination symptoms in childhood and adulthood. J Urol 2005; 174:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/57\">",
"      Feng WC, Churchill BM. Dysfunctional elimination syndrome in children without obvious spinal cord diseases. Pediatr Clin North Am 2001; 48:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/58\">",
"      O'Regan S, Yazbeck S. Constipation: a cause of enuresis, urinary tract infection and vesico-ureteral reflux in children. Med Hypotheses 1985; 17:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/59\">",
"      Lucanto C, Bauer SB, Hyman PE, et al. Function of hollow viscera in children with constipation and voiding difficulties. Dig Dis Sci 2000; 45:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/60\">",
"      O'Regan S, Yazbeck S, Schick E. Constipation, bladder instability, urinary tract infection syndrome. Clin Nephrol 1985; 23:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/61\">",
"      Chen JJ, Mao W, Homayoon K, Steinhardt GF. A multivariate analysis of dysfunctional elimination syndrome, and its relationships with gender, urinary tract infection and vesicoureteral reflux in children. J Urol 2004; 171:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/62\">",
"      von Gontard A, Lettgen B, Olbing H, et al. Behavioural problems in children with urge incontinence and voiding postponement: a comparison of a paediatric and child psychiatric sample. Br J Urol 1998; 81 Suppl 3:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/63\">",
"      Bhatia MS, Nigam VR, Bohra N, Malik SC. Attention deficit disorder with hyperactivity among paediatric outpatients. J Child Psychol Psychiatry 1991; 32:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/64\">",
"      Duel BP, Steinberg-Epstein R, Hill M, Lerner M. A survey of voiding dysfunction in children with attention deficit-hyperactivity disorder. J Urol 2003; 170:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/65\">",
"      Robson WL, Jackson HP, Blackhurst D, Leung AK. Enuresis in children with attention-deficit hyperactivity disorder. South Med J 1997; 90:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/66\">",
"      Zink S, Freitag CM, von Gontard A. Behavioral comorbidity differs in subtypes of enuresis and urinary incontinence. J Urol 2008; 179:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/67\">",
"      McKenna PH, Herndon CD. Voiding dysfunction associated with incontinence, vesicoureteral reflux and recurrent urinary tract infections. Curr Opin Urol 2000; 10:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28793/abstract/68\">",
"      Cooper CS, Abousally CT, Austin JC, et al. Do public schools teach voiding dysfunction? Results of an elementary school teacher survey. J Urol 2003; 170:956.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6580 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28793=[""].join("\n");
var outline_f28_7_28793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS OF SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMAL VOIDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DEFINITION OF BLADDER DYSFUNCTION DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DAYTIME URINARY INCONTINENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Overactive bladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Voiding postponement and underactive bladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dysfunctional voiding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Giggle incontinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Vaginal voiding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Primary neck bladder dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Constipation and dysfunctional elimination syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Behavioral and neurodevelopmental issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6580\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6580|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/55/11125\" title=\"figure 1\">",
"      Normal urinary voiding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/9/27798\" title=\"figure 2\">",
"      Ectopic ureter male",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/1/42002\" title=\"figure 3\">",
"      Ectopic ureter female",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6580|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/12/10440\" title=\"picture 1\">",
"      Vincents curtsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39989?source=related_link\">",
"      Ectopic ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40281?source=related_link\">",
"      Etiology and evaluation of nocturnal enuresis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25384?source=related_link\">",
"      Evaluation and diagnosis of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7178?source=related_link\">",
"      Management of nocturnal enuresis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/2/21538?source=related_link\">",
"      Patient information: Daytime wetting (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38193?source=related_link\">",
"      Patient information: Vesicoureteral reflux in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37592?source=related_link\">",
"      Toilet training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15288?source=related_link\">",
"      Urinary tract complications of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_7_28794="Overview of the management of tetralogy of Fallot";
var content_f28_7_28794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of tetralogy of Fallot",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/7/28794/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28794/contributors\">",
"     Thomas Doyle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28794/contributors\">",
"     Ann Kavanaugh-McHugh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28794/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/7/28794/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28794/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28794/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/7/28794/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28794/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/7/28794/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetralogy of Fallot (TOF) includes the following major features (",
"    <a class=\"graphic graphic_figure graphicRef82493 \" href=\"UTD.htm?39/35/40501\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Right ventricular outflow tract obstruction",
"     </li>",
"     <li>",
"      Ventricular septal defect (VSD)",
"     </li>",
"     <li>",
"      Deviation of the origin of the aorta to the right so that it overrides the VSD",
"     </li>",
"     <li>",
"      Concentric right ventricular (RV) hypertrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TOF accounts for approximately 10 percent of all cases of congenital heart disease and is one of the most common cyanotic congenital heart defects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/1\">",
"     1",
"    </a>",
"    ]. Reparative surgery, which is usually performed electively in the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/2\">",
"     2",
"    </a>",
"    ], permits over 85 percent of children with TOF to survive to adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/3\">",
"     3",
"    </a>",
"    ]. TOF is also the most common cyanotic malformation to reach adulthood without surgical repair.",
"   </p>",
"   <p>",
"    The clinical presentation of patients with TOF depends chiefly upon the degree of RV outflow obstruction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with severe obstruction have inadequate pulmonary flow, and typically present in the immediate newborn period with profound cyanosis",
"     </li>",
"     <li>",
"      Children with moderate obstruction and balanced pulmonary and systemic flow usually come to clinical attention during elective evaluation for a murmur",
"     </li>",
"     <li>",
"      Children with minimal obstruction may present with increased pulmonary blood flow and heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most children with TOF are symptomatic and cyanotic. In general, the earlier the onset of systemic hypoxemia, the more likely that severe pulmonary stenosis or atresia is present. Later, dyspnea on exertion, clubbing, and erythrocytosis are common.",
"   </p>",
"   <p>",
"    An overview of the management of TOF, including postoperative sequelae, complications, and issues related to pregnancy are discussed here. The pathophysiology, clinical features, and diagnosis of this defect are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with TOF undergo intracardiac repair. Severely symptomatic cyanotic newborns may require intravenous prostaglandin (also known as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    ) to maintain ductal patency and pulmonary flow pending more definitive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An occasional infant with increased pulmonary blood flow requires",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and diuretics for heart failure. These drugs should be discontinued as RV obstruction progresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11096360\">",
"    <span class=\"h2\">",
"     Tet spells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercyanotic (or \"tet\") spells can be associated with almost total occlusion of the RV outflow tract (RVOT) and profound cyanosis. They typically occur when an infant becomes agitated, sometimes upon awakening crying from a deep sleep.",
"   </p>",
"   <p>",
"    Hypercyanotic &ldquo;tet&rdquo; spells may require rapid and aggressive step-wise treatment that starts with placement of the patient in a knee-chest position to increase systemic vascular resistance, which promotes movement of blood from the right ventricle into the pulmonary circulation rather than the aorta. This may be followed by more aggressive therapy of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and a fluid bolus. The mechanism of action of morphine is unclear, while fluids improve RV filling and pulmonary flow. The role of bicarbonate therapy to treat an associated lactic acidosis is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=see_link&amp;anchor=H23#H23\">",
"     \"Approach to the child with metabolic acidosis\", section on 'Bicarbonate therapy in neonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the above measures fail, intravenous beta blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    ) can be administered. The presumed mechanism of benefit is relaxation of the right ventricular outflow tract (RVOT) with improved pulmonary blood flow. If this is insufficient, systemic afterload can be increased with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    , which, as with assumption of the knee-chest position, promotes right ventricular flow into the pulmonary circulation rather than the aorta.",
"   </p>",
"   <p>",
"    Emergent complete surgical repair or an emergency aorticopulmonary shunt (ie, Blalock-Taussig shunt) is necessary if all of these measures fail.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for antibiotic prophylaxis to prevent bacterial endocarditis in children with congenital heart disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surgical procedures",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69025840\">",
"    <span class=\"h3\">",
"     Blalock-Taussig shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blalock and Taussig first reported successful surgical palliation of TOF in 1945 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/5\">",
"     5",
"    </a>",
"    ]. The procedure, which has since come to bear their names, used a subclavian artery to create an aorta-to-pulmonary artery connection. The success of this procedure changed the previously dismal outlook for this disease. The technique has been modified and is now usually performed using a Gortex tube to create the connection. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Subclavian steal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although most children with TOF undergo intracardiac repair as their initial intervention, the principle of the Blalock-Taussig shunt remains an important palliative procedure for infants who may not be acceptable candidates for intracardiac repair due to prematurity, hypoplastic pulmonary arteries, or coronary artery anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69025847\">",
"    <span class=\"h3\">",
"     Intracardiac repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracardiac repair of TOF was reported by Lillehi in 1954 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/6\">",
"     6",
"    </a>",
"    ]. It consists of patch closure of the ventricular septal defect and enlargement of the RVOT. The latter is accomplished by relieving pulmonary stenosis, resecting infundibular and subinfundibular muscle bundles and if necessary by a transannular patch, creating unobstructed flow from the RV into the pulmonary arteries (",
"    <a class=\"graphic graphic_figure graphicRef67062 \" href=\"UTD.htm?27/31/28145\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The goal of initial surgery should be to relieve all sources of RVOT obstruction, including that located at the site of insertion of the ductus arteriosus, which may be difficult to diagnose in the neonate before ductal closure. When feasible, a transatrial approach is utilized to access the right ventricular outflow tract and close the ventricular septal defect. This approach is most likely to be successful in patients with discrete infundibular stenosis and an adequate pulmonary annulus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/7\">",
"     7",
"    </a>",
"    ]. A transpulmonary approach allows additional access to the right ventricular outflow tract, however, ventriculotomy with right ventricular outflow tract enlargement and even transannular patch may be required for adequate relief of outflow tract obstruction.",
"   </p>",
"   <p>",
"    A transannular patch of the RVOT renders the pulmonary valve incompetent, which may have significant long-term hemodynamic and electrophysiologic consequences, especially if severe. Currently, surgical approaches emphasize maintaining pulmonary valve competence where possible. A \"valve sparing approach\" is easily applied to individuals with adequate pulmonary annulus size. However, in patients with borderline pulmonary valve annulus sizes, this approach necessitates balancing some degree of residual right ventricular outflow tract obstruction against the obligate insufficiency associated with a transannular patch.",
"   </p>",
"   <p>",
"    The ability to preserve the pulmonary valve was illustrated in one study in which 80 percent of children who underwent repair had a valve sparing procedure, primarily through a transatrial-transpulmonary approach [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/8\">",
"     8",
"    </a>",
"    ]. Residual outflow tract gradients fell in the valve-sparing group at a mean follow-up of 34 months (range 4 to 84 months) compared to a slight increase in the patients with transannular patch repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/8\">",
"     8",
"    </a>",
"    ], similar to results from another case series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/7\">",
"     7",
"    </a>",
"    ]. Reoperation rates for patients undergoing valve sparing procedures were not statistically different from the reoperation rate for patients with a transannular patch repair and were low for both groups. Use of an initial palliative shunt appeared to improve the success of a valve sparing approach, especially in symptomatic young infants with small pulmonary valves.",
"   </p>",
"   <p>",
"    At the present time, there is not general consensus upon the size of the pulmonary annulus and the acceptable degree of residual outflow tract obstruction that is amenable to a valve sparing approach [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Guidelines continue to evolve as additional data become available. Though there is increasing emphasis on preservation of pulmonary valve function, data from the Society of Thoracic Surgeons database demonstrates that ventriculotomy and transannular patch repair is the most common strategy for primary repair of TOF and following palliative intervention for TOF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternate procedure is insertion of a valved conduit from the RV to the distal main pulmonary artery (",
"    <a class=\"graphic graphic_figure graphicRef67062 \" href=\"UTD.htm?27/31/28145\">",
"     figure 2",
"    </a>",
"    ). However, stenosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regurgitation of the conduit prosthetic valve, as well as stenosis of the conduit, can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Chronic pulmonary regurgitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative shunts were initially reserved for infants, and intracardiac repair for children, but the excellent results of intracardiac repair for neonates and infants have made it the current treatment of choice for all patients with TOF in most centers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/10,12-15\">",
"     10,12-15",
"    </a>",
"    ]. Surgery is usually performed electively in the first year of life and can be performed in the first three months, if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/13\">",
"     13",
"    </a>",
"    ]. Intracardiac repair is also performed in asymptomatic acyanotic infants (pink variant) with a low morbidity and mortality; this approach may allow normal growth of the RVOT and pulmonary annulus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intracardiac repair of TOF is now rarely postponed until adulthood. However, patients who had palliative surgery as children often require reoperation as adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Short-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative mortality after intracardiac repair in neonates or young infants has ranged from 0 to 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/12-14,17\">",
"     12-14,17",
"    </a>",
"    ]. In a review of 99 children, actuarial survival rates were 94 percent at one year and 92 percent at five years; the freedom from catheterization rates at these time periods were 86 and 73 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/14\">",
"     14",
"    </a>",
"    ]. The mortality rate approaches zero by six months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excellent results can be obtained even with surgery in the first months of life. A retrospective study examined outcomes in 90 patients less than four months of age undergoing surgical primary repair of TOF between 1995 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/17\">",
"     17",
"    </a>",
"    ]. There were no early deaths within 30 days of surgery, and there were two late deaths after a median follow-up time of 4.7 years. Seven of the 88 survivors required reoperation, and 12 reintervention. There was no difference in outcome between infants younger than 28 days who underwent surgery because of duct-dependent pulmonary circulation or severe hypoxia, and older infants who underwent early elective repair after 28 days of age.",
"   </p>",
"   <p>",
"    Infants who undergo intracardiac repair may require a second surgical procedure. In a report of 30 children less than 90 days of age, the one and five year freedom from reoperation rates was 93 and 66 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/12\">",
"     12",
"    </a>",
"    ]. The main indications for reoperation were left pulmonary artery branch stenosis and residual RVOT obstruction. Children with pulmonary atresia are more likely to require reoperation than those with pulmonary stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The operative risk appears to be somewhat greater when intracardiac repair is performed in adults. In 2 series of 62 patients, there was a 2.5 percent operative mortality, a 16 percent in-hospital mortality, and a 35 to 50 percent incidence of ventricular arrhythmias at long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98216791\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After surgical correction, echocardiography is performed to detect any residual septal defects, determine the severity of pulmonary insufficiency, determine if there is persistent RVOT obstruction and, if so, ascertain the severity and the site of obstruction, assess right and left ventricular size, function and wall motion, and detect any aortic root dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aortic valve insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2174495\">",
"    <span class=\"h2\">",
"     Pulmonary insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of pulmonary insufficiency post-repair can be assessed by comprehensive echo-Doppler evaluation of right ventricular size, color Doppler evaluation of the width of the regurgitant jet at the annulus, and demonstration of retrograde flow in the main and branch pulmonary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Determination of the continuous wave Doppler signal density profile and measurement of pressure half time of the pulmonary regurgitant jet may also be helpful in determining the hemodynamic significance of pulmonary valve insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pulmonary regurgitant index by m-mode echocardiography (PRIME), which is the variation in the right pulmonary artery diameter in systole and diastole, may also be used to detect significant pulmonary valve insufficiency. PRIME correlates with pulmonary regurgitant fraction as measured by magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/23\">",
"     23",
"    </a>",
"    ]. In a cohort of pediatric and adult patients post repair of TOF evaluated by both echocardiography and MRI, the best univariate predictor of severe insufficiency (defined as a regurgitant fraction by MRI of greater than 40 percent) was the presence of diastolic flow in the branch pulmonary arteries. The presence of diastolic reverse flow in the main or pulmonary artery, pulmonary regurgitant jet width greater than 50 percent of the pulmonary annulus and pressure half time of the pulmonary regurgitant jet were also significant predictors of severe pulmonary insufficiency as assessed by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Chronic pulmonary regurgitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2174480\">",
"    <span class=\"h2\">",
"     RV function and size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Qualitative two dimensional assessment of right ventricular wall motion should be included in the evaluation of all postoperative patients. Quantitative assessment of right ventricular size and ejection fraction is better performed with other modalities, including three-dimensional echocardiography and MRI. MRI has a central role in quantitative right ventricular assessment and in current patient management, especially in those who may require pulmonary valve replacement. Three-dimensional echocardiographic volumes and ejection fractions show reasonable correlation with MRI derived values. However, accuracy decreases with increasing right ventricular volume [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/25\">",
"     25",
"    </a>",
"    ], and dependence on good acoustic windows may limit the utility of this modality in older and larger patients, a shortcoming not shared by MRI. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pulmonary valve replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Though MRI is the gold standard for evaluation of right ventricular size and performance, the widespread availability and ease of performance of two-dimensional echocardiography continues to prompt investigators to search for measures of right ventricular performance and ejection fraction that correlate with the MRI parameters that currently guide patient management. In a study of 101 adult patients after repair of TOF, right ventricular end diastolic area measured in the apical four chamber view and indexed to body surface area was used to generate linear regression equations predicting right ventricular volumes as measured by MRI. In patients undergoing serial evaluation, this mathematical model based on an echocardiographic parameter was able to detect serial changes in right ventricular volume as assessed by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/26\">",
"     26",
"    </a>",
"    ]. In this study, comparison of two dimensional echocardiographic evaluations to MRI data identified contributions from both the right ventricular outflow tract and right ventricular body as important determinants of global right ventricular performance. In patients with normal right ventricular ejection fractions by MRI, there was increased contraction of the right ventricular body compensating for decreased systolic function of the right ventricular outflow tract. A regression equation using right ventricular outflow tract shortening fraction from parasternal long axis images, and fractional area change from apical images allowed accurate echocardiographic estimation of right ventricular ejection fraction as measured by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Residual right ventricular outflow tract obstruction in postoperative patients with TOF should be sought. Right ventricular pressure can be determined by adding the estimated right atrial pressure to the pressure gradient derived from the tricuspid regurgitation velocity using the modified Bernoulli equation. When a residual VSD is present, Doppler interrogation of the defect can also be used to estimate right ventricular pressure. In many patients, the peak gradient obtained by applying the modified Bernoulli equation to the flow velocity across the defect allows for a reasonable assessment of right ventricular pressure when subtracted from the systemic blood pressure. However, in other patients, the mean or end diastolic gradient better correlates with measured gradients in the catheterization laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2175884\">",
"    <span class=\"h2\">",
"     Aortic root and valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals who have undergone repair of TOF should also be evaluated for aortic root dilation and aortic valve insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2175891\">",
"    <span class=\"h2\">",
"     New echocardiographic tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;New echocardiographic modalities may offer further insight into ventricular performance in the postoperative patient. Strain and strain rate determination by color Doppler and speckle tracking can be used to identify regional abnormalities of myocardial deformation, which may be markers for early ventricular dysfunction. Ventricular twist and torsion are also being evaluated in this population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities of right ventricular and septal deformation have been demonstrated in children and adults post-repair of TOF [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/31-38\">",
"       31-38",
"      </a>",
"      ]. These findings have been associated with increased severity of pulmonary insufficiency, abnormal right ventricular ejection fraction by MRI, and with the presence of electrical abnormalities. Changes in strain and strain rate may precede deterioration in ejection fraction, and have been correlated with exercise capacity. These findings suggest that myocardial strain and strain rate assessment may detect abnormalities in ventricular performance at an earlier stage than other measures of systolic performance, and may have a role in future algorithms for management of the patient with TOF.",
"     </li>",
"     <li>",
"      Abnormalities of left ventricular strain and strain rate have also been reported after surgical repair, and have been associated with both degree of right ventricular volume load and with exercise capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/35\">",
"       35",
"      </a>",
"      ]. Vector velocity imaging has been used to document abnormalities in left ventricular longitudinal strain, and like speckle tracking, has been used in the evaluation of interventricular dyssynchrony in patients post repair [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/36,39\">",
"       36,39",
"      </a>",
"      ]. Abnormalities of left ventricular strain may be seen in the first two decades after repair and have been demonstrated before abnormalities of left ventricular ejection fraction by MRI, again suggesting that these parameters may reflect an earlier stage of abnormal ventricular performance. The existence of a relationship between abnormalities of apical left and right ventricular apical strain and left ventricular twist may suggest that apical ventricular-ventricular interactions may constitute the earliest adverse interventricular interactions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of these modalities in our understanding and management of patients with TOF will continue to evolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of surgical repair of TOF include pulmonary regurgitation, residual RVOT obstruction, RV wall motion abnormalities, and arrhythmias including atrial tachycardia and ventricular tachycardia (VT), which is usually monomorphic.",
"   </p>",
"   <p>",
"    The frequency with which these complications occur was illustrated in a review of 95 patients who underwent surgical repair at a mean age of 13 years and were last evaluated at a mean age of 38 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/40\">",
"     40",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients were clinically well at the end of the study: 80 percent were New York Heart Association (NYHA) class I, and 17 percent class II (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Sixteen patients (17 percent) had sustained tachyarrhythmias: eight atrial and eight ventricular, with one sudden cardiac death (SCD).",
"     </li>",
"     <li>",
"      Fifteen patients (16 percent) underwent RV outflow reoperation at a mean of 20 years following the initial surgery. All 15 operations included pulmonary valve replacement: 14 for pulmonary regurgitation (with RV outflow obstruction in six) and one for RV outflow obstruction. These reoperations resulted in improved NYHA class and restoration of RV exercise reserve.",
"     </li>",
"     <li>",
"      Right and left ventricular ejection fractions at rest and during exercise were within the normal range and remained stable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic pulmonary regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, intracardiac repair with a transannular RVOT patch can result in chronic severe pulmonary regurgitation; this complication is less frequent in patients who receive a valved conduit from the RV to the distal pulmonary artery. In a report of 100 consecutive patients with repaired TOF, cardiac magnetic resonance imaging at a median of 20 years after surgery showed a significantly greater pulmonary regurgitant fraction in those with a patch repair compared to those with a conduit (36 versus 18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant chronic pulmonary regurgitation leads to RV enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The degree of RV enlargement is less pronounced in patients with a conduit. In the above report, the median RV end-diastolic volume index was significantly higher in patients with a patch repair (122 versus 106",
"    <span class=\"nowrap\">",
"     mL/m2",
"    </span>",
"    in those with a conduit; normal range 70 to 98",
"    <span class=\"nowrap\">",
"     mL/m2).",
"    </span>",
"    All patients in this study with RV end systolic volumes greater than 95",
"    <span class=\"nowrap\">",
"     mL/m2",
"    </span>",
"    had evidence of right ventricular dysfunction by magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with RV dysfunction may develop decreased exercise tolerance, right heart failure, and arrhythmias (ie, VT, atrial flutter, and atrial fibrillation). The decline in RV function can also lead to left ventricular dysfunction due to septal shift and",
"    <span class=\"nowrap\">",
"     ventricular/ventricular",
"    </span>",
"    interaction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/41\">",
"     41",
"    </a>",
"    ]. In a multicenter study involving 11 adult congenital heart disease centers, there was echocardiographic evidence of left ventricular systolic dysfunction in 21 percent of adult patients after repair of TOF, with 6 percent felt to have evidence of moderate to severely decreased left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pulmonary valve replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A surgical prosthetic valve may be necessary to restore pulmonary valve competence and improve RV function and functional status in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Although optimal timing of pulmonary valve replacement remains uncertain, this option should be considered in patients with symptoms related to pulmonary valve regurgitation, moderate or severe RV volume overload, RV dysfunction, and clinical arrhythmias attributable to the right heart",
"    <span class=\"nowrap\">",
"     enlargement/dysfunction",
"    </span>",
"    from pulmonary valve regurgitation.",
"   </p>",
"   <p>",
"    MRI studies have provided helpful information on right ventricular volume load, which has been used to develop guidelines for pulmonary valve replacement. From these studies, there appears to be a threshold degree of dilation beyond which restoration of normal right ventricular volume cannot be achieved with valve replacement. Normal right ventricular volumes may not be restored in patients with preoperative end diastolic volumes exceeding 160 to 170",
"    <span class=\"nowrap\">",
"     mL/m2",
"    </span>",
"    or end systolic volumes exceeding 80 to 85",
"    <span class=\"nowrap\">",
"     mL/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to note that while right ventricular volumes decreased significantly with valve replacement, ejection fractions were not significantly changed by valve replacement. These data, paired with exercise data in this population, underscore the need to proceed with pulmonary valve replacement before RV dysfunction develops. Although aerobic exercise capacity improves substantially after pulmonary valve replacement, studies have shown that patients will fail to demonstrate improvement in RV function and exercise capacity when intervention occurs too late in the disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this population, there are many factors that promote the development of arrhythmias. In particular, right atrial and ventricular dilation has been linked to the evolution of both atrial and ventricular arrhythmias. Because the slowed conduction arrhythmogenic substrate of monomorphic ventricular tachycardia is usually along the ventriculotomy scar and severe pulmonary regurgitation serves as a trigger, pulmonary valve replacement with revision of the scar may remove both substrate and trigger. Persistence of a reentrant substrate requires electrophysiologic mapping and radiofrequency ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A growing experience with percutaneous pulmonary valve implantation has demonstrated it to be an attractive alternative for appropriate patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Percutaneous pulmonary valve implantation (PPVI) has been successfully performed in patients with pulmonary regurgitation resulting in improved cardiac function and exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/56\">",
"     56",
"    </a>",
"    ]. In the majority of cases to date, a bovine jugular vein valve mounted in a balloon expanded intravascular stent has been used for implantation. Because the size of the bovine jugular valve is limited to 22mm or less, it cannot be used in patients with dilated and aneurismal outflow tract anatomy, which is seen in many patients following transannular patch repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/57\">",
"     57",
"    </a>",
"    ]. In some cases with large right ventricular outflow tract, this valve has been used in hybrid surgical procedures. Ongoing research efforts are focused upon the use of a self-expandable stent to reduce the size of the outflow tract, so that the valve can be successfully deployed in large outflow tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, a percutaneous valve created by mounting bovine pericardial leaflets to a slotted, stainless steel stent has been developed, with promising early results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/59\">",
"     59",
"    </a>",
"    ]. This valve is available in 23 and 26 mm diameters.",
"   </p>",
"   <p>",
"    Reintervention may be required for stent fracture, device failure with recurrent stenosis, or residual stenosis not relieved by the stent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/60\">",
"     60",
"    </a>",
"    ]. Relieving conduit obstruction with bare metal stent implantation prior to implantation of the percutaneous pulmonary valve may diminish the risk of stent fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/61\">",
"     61",
"    </a>",
"    ]. Acute life threatening complications of this percutaneous pulmonary valve implantation are rare. In a case series of 152 patients undergoing PPV, six patients had acute complications requiring rescue surgery including homograft rupture, dislodgement of the stented valve, occlusion of the right pulmonary artery, and compression of the left coronary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, degeneration of the tissue valves can be expected over time and data regarding this issue are accruing. Despite the above issues, early results are promising, and this evolving technology is an exciting option for this patient group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Residual right ventricular outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Residual RVOT obstruction can persist after the original intracardiac operation due to hypertrophied subvalvar muscle, annular hypoplasia, pulmonary valve stenosis, supravalvar pulmonary stenosis, or branch pulmonary artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/12\">",
"     12",
"    </a>",
"    ]. Mild obstruction is usually well tolerated, but significant obstruction may require reoperation or catheter-based intervention. Relief of pulmonary artery stenosis by balloon dilation or stenting may be necessary prior to pulmonary valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atrial tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial tachyarrhythmias are common after repair of TOF.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 242 patients, 29 (12 percent) developed sustained episodes of atrial tachyarrhythmia at a mean of 16 years after repair [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second series, 29 of 793 (4 percent) had sustained atrial flutter or atrial fibrillation at a mean of 21 years after repair [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multicenter review of 566 adult patients (mean age 36.8 years &plusmn; 12), 43 percent had a sustained arrhythmia or arrhythmia intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/66\">",
"       66",
"      </a>",
"      ]. The frequency of arrhythmias markedly increased after 45 years of age. The prevalence of atrial tachyarrhythmia was 20 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of atrial tachyarrhythmias in adults may be associated with an increase in morbidity due to heart failure, reoperation, ventricular tachycardia, stroke, or death (69 versus 30 percent in the absence of atrial arrhythmia in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/64\">",
"     64",
"    </a>",
"    ]. Predictors of atrial tachyarrhythmias include older age at the time of repair (25 versus 10 years in the preceding series), greater cardiothoracic ratio, and tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A right bundle branch block pattern on electrocardiogram is the rule following intracardiac repair. As a result, most atrial tachyarrhythmias are wide complex regardless of their origin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=see_link\">",
"     \"Management and evaluation of wide QRS complex tachycardia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ventricular tachyarrhythmias and SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachyarrhythmias, including sustained, monomorphic ventricular tachycardia (VT) and sudden cardiac death (SCD), can occur early after surgery or years after intracardiac repair of TOF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/18,19,67-69\">",
"     18,19,67-69",
"    </a>",
"    ]. In a study of 793 patients followed for a mean of 21 years after surgery, sustained monomorphic VT occurred in 4.2 percent, and 2 percent died suddenly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/65\">",
"     65",
"    </a>",
"    ]. In the previously mentioned multicenter study of 566 adult patients, the prevalence of ventricular arrhythmias was 14.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both sustained and nonsustained monomorphic VT can be induced by programmed electrical stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. The arrhythmogenic site is usually along the right ventriculotomy scar [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical, electrocardiographic, echocardiographic, and hemodynamic risk factors have been identified for ventricular tachyarrhythmias or SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/3,65,67,69,74-78\">",
"     3,65,67,69,74-78",
"    </a>",
"    ]. The clinical risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age at repair [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/3,65\">",
"       3,65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Male sex [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Worse heart failure as assessed by New York Heart Association class [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Repair via a right ventriculotomy rather than an atriotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are two major electrocardiographic risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient complete heart block persisting beyond the third postoperative day [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      QRS duration &ge;180 ms and rapid development of QRS prolongation within the first six months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/65,79\">",
"       65,79",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Single or bigeminal monomorphic ventricular premature beats on Holter monitor or exercise stress testing are not predictive of a sustained ventricular tachyarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiographic and hemodynamic factors are additional risk factors. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic RV volume or pressure overload [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/3,67,76\">",
"       3,67,76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Higher residual RVOT gradient [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Moderate to severe pulmonary regurgitation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/53,65,67\">",
"       53,65,67",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of chronic pulmonary regurgitation has been demonstrated by the observation that pulmonary valve replacement can reduce the incidence of sustained monomorphic VT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Electrophysiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic (EP) testing has been used to stratify patients for risk of VT or sudden cardiac death (SCD) after repair of TOF. This approach was evaluated in a multicenter study of 252 patients who underwent EP study at a mean of 12 years after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/80\">",
"     80",
"    </a>",
"    ]. Sustained monomorphic VT was induced in 76 (30 percent) and sustained polymorphic VT in 11 (4 percent). At a mean follow-up of seven years, 62 patients (25 percent) had sustained VT or SCD. The sensitivity and specificity of sustained VT on EP testing for subsequent VT or SCD were 77 and 80 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Course and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac death (SCD) is an important cause of mortality after intracardiac repair of TOF. In three large series of patients followed for 21 to 36 years, SCD occurred in 2.0, 2.7, and 9 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/65,81,82\">",
"     65,81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiofrequency ablation has been effective in patients with inducible VT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/73,83-85\">",
"     73,83-85",
"    </a>",
"    ]. Other successful approaches include intraoperative mapping with ablation, revision of the ventriculotomy scar during surgery for pulmonary regurgitation, and resection of an RVOT aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/67,71,72\">",
"     67,71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data are available on outcomes with implantable cardioverter-defibrillator (ICD) therapy in patients with TOF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. In one multicenter study of 121 patients (median age 33.3 years), ICD were implanted for primary (68 patients, 56 percent) or secondary prevention (53 patients, 44 percent) of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/85\">",
"     85",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a median follow-up of 3.7 years after implantation, approximately 30 percent of patients received at least one appropriate and effective ICD discharge. The median detected ventricular tachyarrhythmia rate was 213 bpm.",
"     </li>",
"     <li>",
"      Nine patients died during the follow-up period, four due to heart failure and five to SCD. Three of the five SCD deaths were attributed to presumed electromechanical dissociation, because there were no tachyarrhythmias detected on ICD interrogation. One patient died after voluntary ICD inactivation and one died after a prolonged ventricular tachyarrhythmia storm with exhaustion of ICD therapy.",
"     </li>",
"     <li>",
"      Inappropriate shocks occurred in 6 percent of patients yearly. In addition, 36 patients experienced complications; six due to periprocedural complications (eg, pneumothorax or hemothorax), seven with late generator-related complications (eg, chronic pain, late infection, or malfunction), and 25 had lead-related complications (eg, lead dislodgement, failure, or fracture).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Subclavian steal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential complication of the Blalock-Taussig anastomosis is vertebrobasilar ischemia due to a subclavian steal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=see_link\">",
"     \"Subclavian steal syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=see_link&amp;anchor=H2#H2\">",
"     \"Subclavian steal syndrome\", section on 'Physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88361110\">",
"    <span class=\"h2\">",
"     Mortality and cardiac morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival rate of children with TOF is excellent. This was illustrated by the United Kingdom Northern Congenital Abnormality survey of children born between 1985 and 2003 that reported a 20-year estimated survival rate of 80.8 percent for children diagnosed with TOF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term outcomes are generally good in patients with TOF but there is a risk of cardiac complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single institution study described the long-term outcome in 570 patients undergoing total repair of TOF either as a primary repair or following initial palliative surgery between 1953 and 2008. In this series, early mortality was 7.2 percent, and total late mortality was 7.9 percent. In the final decade of the study, there were no early deaths. Patients undergoing transannular patch repair had a significantly increased risk of reoperation, though an almost linear decrease in reoperation free survival was noted during the fifty-year follow-up period, regardless of surgical strategy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large case series of 1181 patients (born before 1984) who underwent corrective surgery (median age 6.9 years) at a single institution, the survival rate to adulthood (&gt;18 years of age) was 85 percent at last follow-up in 2002 and 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/90\">",
"       90",
"      </a>",
"      ]. In the cohort of 840 adult survivors, right-sided cardiac findings included moderate to severe pulmonary regurgitation (54 percent) and mild right ventricular outflow obstruction (one-third of the patients), and left-sided findings of mild aortic regurgitation (50 percent), and left ventricular hypertrophy and dilation. Surgical reoperations were performed in 19 percent of adult survivors. Cardiorespiratory symptoms were reported in 45 percent of the cohort, which included palpitations (27 percent), dyspnea (21 percent), and chest pain (17 percent). Older patients were more likely to report poorer physical conditioning and were more likely to have echocardiographic abnormalities.",
"     </li>",
"     <li>",
"      A report from the Euro Heart Survey of adult congenital heart disease described five-year outcomes in 811 adults with TOF (mean age 26 years), 40 percent of whom had a previous patch repair [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/91\">",
"       91",
"      </a>",
"      ]. The mortality rate at five-year follow-up was 1.3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/91\">",
"       91",
"      </a>",
"      ]. Most patients had few or no symptoms, 93 percent were NYHA class I or II, and 56 percent were on no medications. Diuretics, beta blockers, and angiotensin converting enzyme inhibitors were each taken in 11 to 15 percent;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or other vitamin K antagonist in 9 percent; and antiarrhythmic drugs in 4 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these reports demonstrate good long-term survival rates, they may underestimate outcome expectations of children currently undergoing repair. Since 1985, major changes in the management of children with TOF, such as repair in infancy and improved surgical technique, are expected to improve long-term survival.",
"   </p>",
"   <p>",
"    Myocardial fibrosis may have an adverse effect on long-term outcomes. This association was evaluated in 92 adults who had undergone TOF repair using cardiovascular magnetic resonance imaging (CMR) and late gadolinium enhancement (LGE), which is considered a marker of fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/92\">",
"     92",
"    </a>",
"    ]. LGE was seen in all patients at the site of TOF repair; those with right ventricular LGE scores above the median were much more likely to be symptomatic (38 versus 8 percent NYHA class II or greater), had a lower right ventricular ejection fraction, and had a higher rate of arrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Neurodevelopmental outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up of children with TOF demonstrate impairment in neurodevelopmental outcome. In two studies, children with TOF (5 to 12 years after surgical correction), when compared with normal healthy children, had lower scores on intelligence tests, mild impairment of fine motor skills, and difficulties with language tasks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. It is important for care providers to consider the long-term developmental outcome when caring for children with TOF.",
"   </p>",
"   <p>",
"    As a result, all children with TOF should undergo appropriate surveillance, screening and, if appropriate, referral for neurodevelopmental impairment as recommended in a 2012 scientific statement from the American Heart Association [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link\">",
"     \"Developmental-behavioral surveillance and screening in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TETRALOGY OF FALLOT IN THE ADULT PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to separate the management issues of the adult patient with TOF from those of patients earlier in the postoperative course. The issues in the care of the postoperative patient with TOF are not restricted to patients in one age group but rather are part of a continuum.",
"   </p>",
"   <p>",
"    As previously noted, the majority of patients with TOF do well with excellent long-term postoperative survival and with the majority of patients in NYHA class I or II. This excellent long term outcome depends on appropriate surveillance for evidence of evolving ventricular dilation and dysfunction, particularly in the setting of significant pulmonary valve insufficiency, which may warrant valve replacement. Significant residual right ventricular outflow tract obstruction, especially when coupled with the stress of volume load poses a risk for ventricular dysfunction and may require operative or catheter based intervention. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Postoperative complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Appropriate surveillance for the evolution of atrial and ventricular arrhythmias is also essential in this population, and are more commonly, seen in patients with residual ventricular volume load",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    outflow tract obstruction. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Atrial tachyarrhythmias'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Ventricular tachyarrhythmias and SCD'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Dilation of the aortic root is common and may be progressive in postoperative patients with TOF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/96\">",
"     96",
"    </a>",
"    ]. As a result, aortic root size should be monitored periodically with echocardiography or another imaging modality. Increasing aortic valve insufficiency may be seen in the setting of aortic root dilation and may require aortic valve replacement. There are rare reports of aortic dissection in the setting of aortic root dilation in this population. However, there are presently no guidelines for medical or surgical management in tetralogy patients with aortic root dilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88360281\">",
"    <span class=\"h2\">",
"     Primary repair in adulthood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is now a rare event, TOF remains the most common cyanotic malformation to reach adulthood without surgical repair. Even in older adult patients, complete repair is feasible resulting in improved function although there is an increased operative risk compared to younger patients. This was illustrated in one case series of 52 patients who underwent repair after 40 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/97\">",
"     97",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About half of the patients had previous palliative surgery at a mean age of 17 &plusmn; 11 years.",
"     </li>",
"     <li>",
"      Procedures for TOF repair included pulmonary valve replacement (n = 10), transannular patch (n = 10), and native pulmonary valve preservation (n = 32).",
"     </li>",
"     <li>",
"      Three patients died during the perioperative period. During the mean follow-up of 15 years (range 0.7 to 38 years), 29 of the 49 remaining survivors died. The 10 year survival rate was lower compared with age- and sex-matched population (73 versus 91 percent) and compared with patients with TOF operated at a younger age (expected 20 year survival of 86 percent).",
"     </li>",
"     <li>",
"      Of the 49 survivors, 42 had improvement in their NYHA functional class and only five patients remained in functional class III or IV (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of adult patients with cyanotic congenital heart disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link\">",
"     \"Medical management of cyanotic congenital heart disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69023439\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fertility appears to be preserved in women with TOF as demonstrated in a review of 811 such women in which the percentage with at least one full-term pregnancy was similar to that in an age-matched sample from the general population (36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/91\">",
"     91",
"    </a>",
"    ]. Women with TOF generally have good maternal and infant outcomes if they do not have severe hemodynamic abnormalities before pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/91,98-101\">",
"     91,98-101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A literature review of studies published between 1985 and 2007 evaluated the rates of complications during completed pregnancies among women with repaired TOF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/102\">",
"     102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to the mother, arrhythmias occurred in 13 of 204 pregnancies (6.4 percent) and heart failure in 5 of 211 pregnancies (2.4 percent). There were no cases of myocardial infarction, stroke, or cardiovascular mortality in 222 pregnancies.",
"     </li>",
"     <li>",
"      With respect to the fetus, premature delivery occurred in 11 of 174 pregnancies (6.3 percent), fetal mortality in 1 of 222 pregnancies (0.5 percent), perinatal mortality in 3 of 222 pregnancies (1.4 percent), small for gestational age in 19 of 211 (9 percent) and recurrent congenital heart disease of any type in 6 of 202 pregnancies (3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further details were reported in the largest single center series of pregnancies complicated by TOF that included 43 women who had 112 pregnancies and 82 births [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/98\">",
"     98",
"    </a>",
"    ]. Almost all were New York Heart Association (NYHA) functional class I or II (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were 30 miscarriages (27 percent) and one term stillbirth. Three women with repaired TOF had three or more spontaneous first trimester pregnancy losses. All three had moderate to severe right ventricular hypertension.",
"     </li>",
"     <li>",
"      Pregnancy outcomes in women who had undergone intracardiac repair were generally similar to those in the general obstetric population. The overall mean birth weight was 3.2 kg.",
"     </li>",
"     <li>",
"      Eight women with unrepaired TOF, five of whom were cyanotic, had 20 successful pregnancies. The mean birth weight in first pregnancies was 2.6 kg and the rates of miscarriage and small for gestational age (SGA) were 20 and 30 percent.",
"     </li>",
"     <li>",
"      Five of the six patients with cardiovascular complications (palpitations, pulmonary edema, peripartum cardiomyopathy, pulmonary embolism) had hemodynamically significant lesions antepartum including severe pulmonary regurgitation with subpulmonary ventricular dysfunction and severe pulmonary hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Findings were similar in an international multicenter study, which reviewed data from 74 patients who had 157 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/103\">",
"     103",
"    </a>",
"    ]. In this series, only 6.5 percent of patients had an NYHA functional class &gt;II. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of miscarriage was 19 percent, and termination was elected in 2.5 percent of pregnancies.",
"     </li>",
"     <li>",
"      Cesarian delivery occurred in 20 percent of deliveries. &nbsp;",
"     </li>",
"     <li>",
"      The mean birthweight was 3.1 kg, and the rates of SGA and prematurity were 19 and 18 percent. There were five prenatal deaths and three postnatal deaths secondary to prematurity, intrauterine growth retardation, and recurrent congenital heart disease. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Maternal cardiovascular complications included arrhythmias (6.5 percent) and heart failure (1.6 percent). Deterioration of NYHA functional class by greater than 1 class from prepregnancy status occurred in 17.7 percent of pregnancies and persisted after delivery in 2 percent of patients. Pulmonary thromboembolism requiring anticoagulation occurred in only one patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Susceptibility to infective endocarditis during delivery is a potential concern. In the 2007 American Heart Association guidelines for antimicrobial prophylaxis, prophylaxis was recommended in only a limited number of settings in patients with congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/104\">",
"     104",
"    </a>",
"    ]. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H2#H2\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Theoretical basis for prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general care for a pregnant woman with congenital heart disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69023655\">",
"    <span class=\"h3\">",
"     Congenital heart disease in the fetus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The offspring of parents with congenital heart disease are at increased risk for congenital heart disease; the risk varies with the specific parental defect and parental sex. In a collaborative study from Britain that evaluated 393 children of 727 parents, the recurrence risk in those with TOF was 3.1 percent (eight of 256 index cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/105\">",
"     105",
"    </a>",
"    ]. A similar rate of recurrent congenital heart disease in offspring (3 percent of pregnancies with maternal TOF) was noted in the above cited review [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 15 percent of patients with TOF and other conotruncal defects have chromosome 22q11.2 microdeletion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/106\">",
"     106",
"    </a>",
"    ]. Screening for 22q11.2 microdeletion should be considered in patients with conotruncal abnormalities prior to pregnancy in order to provide appropriate genetic counseling. In the absence of 22q11.2 deletion, the risk of a fetus having CHD is approximately 4 to 6 percent. In contrast, children born to a parent with 22q11.2 microdeletion have a 50 percent chance of having the deletion and its associated complications.",
"   </p>",
"   <p>",
"    The risk of concordance (recurrence of the specific parental defect) was evaluated in a larger referral series of 6640 pregnancies in which one parent or a sibling had congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/7/28794/abstract/107\">",
"     107",
"    </a>",
"    ]. When the index case had TOF, the concordance rate was 43 percent (three of seven recurrences). The general risk of recurrence of congenital heart disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H31#H31\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Inheritance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/25/2450?source=see_link\">",
"       \"Patient information: Tetralogy of Fallot (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69025778\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reparative surgery is generally performed in most patients with tetralogy of Fallot (TOF) within the first year of life as it has improved mortality and morbidity",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severely symptomatic cyanotic newborns may require intravenous prostaglandin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"       alprostadil",
"      </a>",
"      ) to maintain ductal patency and pulmonary flow pending more definitive therapy. In some infants with increased pulmonary blood flow and heart failure,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      and diuretic therapy may be needed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to surgical repair, patients may develop a hypercyanotic spell (referred to as a &ldquo;tet&rdquo; spell) that occurs during episodes of almost total occlusion of the RV outflow tract (RVOT) and profound cyanosis. Management of tet spells include knee-chest positioning of the patient to increase systemic vascular resistance, the use of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      and fluid bolus, and if the above measures fail, the use of intravenous beta blockers. Emergent complete surgical repair or an emergency aorticopulmonary shunt (ie, Blalock-Taussig shunt) is necessary if all of these measures fail. (See",
"      <a class=\"local\" href=\"#H11096360\">",
"       'Tet spells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical procedures for TOF include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A Blalock-Taussig shunt is used as a palliative procedure in infants who are not acceptable candidates for intracardiac repair due to prematurity, hypoplastic pulmonary arteries, or coronary artery anatomy. (See",
"      <a class=\"local\" href=\"#H69025840\">",
"       'Blalock-Taussig shunt'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whenever possible, we recommend complete intracardiac repair for all patients with TOF. Intracardiac repair consists of patch closure of the ventricular septal defect, and enlargement of the RVOT with relief of all sources of obstruction (",
"      <a class=\"graphic graphic_figure graphicRef67062 \" href=\"UTD.htm?27/31/28145\">",
"       figure 2",
"      </a>",
"      ). Surgery is usually performed electively in the first year of life, and can be performed within the first three months, if necessary. Perioperative mortality is low especially in infants. Infants who undergo intracardiac repair may require subsequent intervention due to pulmonary artery branch stenosis and residual RVOT obstruction (see",
"      <a class=\"local\" href=\"#H69025847\">",
"       'Intracardiac repair'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Postoperative complications'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After surgical correction, echocardiography is performed to detect any residual septal defects, pulmonary valve regurgitation, and persistent RVOT obstruction. The severity and site of obstruction should be assessed. Right and left ventricular size, function, and wall motion, and any aortic root dilation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aortic valve insufficiency should be evaluated. (See",
"      <a class=\"local\" href=\"#H98216791\">",
"       'Postoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of surgical repair of TOF also include arrhythmias: particularly ventricular tachycardia (VT), which is usually monomorphic, and atrial arrhythmias. Patients who underwent transannular patch repair of Tetralogy of Fallot may require pulmonary valve replacement in the second or third decades of life. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Postoperative complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although qualitative two-dimensional echocardiography can evaluate right ventricular wall motion, magnetic resonance imaging (MRI) remains the gold standard for evaluation of right ventricular size, function and performance, and should be performed in patients with severe pulmonary insufficiency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      residual RVOT obstruction to determine appropriate timing of reintervention. (See",
"      <a class=\"local\" href=\"#H98216791\">",
"       'Postoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term outcome of patients after TOF repair is excellent, with estimated 20-year survival rates of over 90 percent. Sudden cardiac death due to arrhythmia and heart failure are the most common causes of late death following surgical repair. Long-term sequelae include cardiac complications following repair, which may require subsequent surgical intervention, and mild to moderate neurodevelopmental impairment. Long-term follow-up care includes monitoring for cardiac complications (eg, arrhythmia, pulmonary and aortic regurgitation, and right-sided obstruction) and neurodevelopment dysfunction. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Long-term outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management issues of the adult patient with TOF are the same as those found in the pediatric population. Complete repair can be performed in the rare patient who has reached adulthood without surgical intervention. Long-term management of adults following surgical repair includes surveillance for similar structural and arrhythmia as seen in the pediatric population. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Tetralogy of Fallot in the adult patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fertility appears to be preserved in women with TOF. In general, maternal and infant outcomes are good if the mother does not have severe hemodynamic abnormalities. However, there is a risk of cardiac complications and deterioration of function. (See",
"      <a class=\"local\" href=\"#H69023439\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is an increased risk (about 3 percent) of congenital heart disease in the offspring of individuals with TOF who do not have 22q11 microdeletion. About 15 percent of TOF patients have 22q11 microdeletion. The offspring of these patients have a 50 percent chance of inheriting this defect with its associated abnormalities. (See",
"      <a class=\"local\" href=\"#H69023655\">",
"       'Congenital heart disease in the fetus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/1\">",
"      Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol 1995; 16:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/2\">",
"      Report of the New England Regional Infant Cardiac Program. Pediatrics 1980; 65:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/3\">",
"      Murphy JG, Gersh BJ, Mair DD, et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med 1993; 329:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/4\">",
"      Abe K, Shimada Y, Takezawa J, et al. Long-term administration of prostaglandin E1: report of two cases with tetralogy of Fallot and esophageal atresia. Crit Care Med 1982; 10:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/5\">",
"      Blalock A, Taussig HB. Surgical treatment of malformations of the heart: In which there is pulmonary stenosis or pulmonary atresia. Am J Med 1945; 128:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/6\">",
"      LILLEHEI CW, COHEN M, WARDEN HE, VARCO RL. The direct-vision intracardiac correction of congenital anomalies by controlled cross circulation; results in thirty-two patients with ventricular septal defects, tetralogy of Fallot, and atrioventricularis communis defects. Surgery 1955; 38:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/7\">",
"      Airan B, Choudhary SK, Kumar HV, et al. Total transatrial correction of tetralogy of Fallot: no outflow patch technique. Ann Thorac Surg 2006; 82:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/8\">",
"      Stewart RD, Backer CL, Young L, Mavroudis C. Tetralogy of Fallot: results of a pulmonary valve-sparing strategy. Ann Thorac Surg 2005; 80:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/9\">",
"      Karamlou T, McCrindle BW, Williams WG. Surgery insight: late complications following repair of tetralogy of Fallot and related surgical strategies for management. Nat Clin Pract Cardiovasc Med 2006; 3:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/10\">",
"      Al Habib HF, Jacobs JP, Mavroudis C, et al. Contemporary patterns of management of tetralogy of Fallot: data from the Society of Thoracic Surgeons Database. Ann Thorac Surg 2010; 90:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/11\">",
"      Chan KC, Fyfe DA, McKay CA, et al. Right ventricular outflow reconstruction with cryopreserved homografts in pediatric patients: intermediate-term follow-up with serial echocardiographic assessment. J Am Coll Cardiol 1994; 24:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/12\">",
"      Hennein HA, Mosca RS, Urcelay G, et al. Intermediate results after complete repair of tetralogy of Fallot in neonates. J Thorac Cardiovasc Surg 1995; 109:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/13\">",
"      Reddy VM, Liddicoat JR, McElhinney DB, et al. Routine primary repair of tetralogy of Fallot in neonates and infants less than three months of age. Ann Thorac Surg 1995; 60:S592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/14\">",
"      Pigula FA, Khalil PN, Mayer JE, et al. Repair of tetralogy of Fallot in neonates and young infants. Circulation 1999; 100:II157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/15\">",
"      Kanter KR, Kogon BE, Kirshbom PM, Carlock PR. Symptomatic neonatal tetralogy of Fallot: repair or shunt? Ann Thorac Surg 2010; 89:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/16\">",
"      Parry AJ, McElhinney DB, Kung GC, et al. Elective primary repair of acyanotic tetralogy of Fallot in early infancy: overall outcome and impact on the pulmonary valve. J Am Coll Cardiol 2000; 36:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/17\">",
"      Tamesberger MI, Lechner E, Mair R, et al. Early primary repair of tetralogy of fallot in neonates and infants less than four months of age. Ann Thorac Surg 2008; 86:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/18\">",
"      Presbitero P, Demarie D, Aruta E, et al. Results of total correction of tetralogy of Fallot performed in adults. Ann Thorac Surg 1988; 46:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/19\">",
"      Dittrich S, Vogel M, D&auml;hnert I, et al. Surgical repair of tetralogy of Fallot in adults today. Clin Cardiol 1999; 22:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/20\">",
"      Bigras JL, Boutin C, McCrindle BW, Rebeyka IM. Short-term effect of monocuspid valves on pulmonary insufficiency and clinical outcome after surgical repair of tetralogy of Fallot. J Thorac Cardiovasc Surg 1996; 112:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/21\">",
"      Joffe H, Georgakopoulos D, Celermajer DS, et al. Late ventricular arrhythmia is rare after early repair of tetralogy of Fallot. J Am Coll Cardiol 1994; 23:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/22\">",
"      Silversides CK, Veldtman GR, Crossin J, et al. Pressure half-time predicts hemodynamically significant pulmonary regurgitation in adult patients with repaired tetralogy of fallot. J Am Soc Echocardiogr 2003; 16:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/23\">",
"      Festa P, Ait-Ali L, Minichilli F, et al. A new simple method to estimate pulmonary regurgitation by echocardiography in operated fallot: comparison with magnetic resonance imaging and performance test evaluation. J Am Soc Echocardiogr 2010; 23:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/24\">",
"      Renella P, Aboulhosn J, Lohan DG, et al. Two-dimensional and Doppler echocardiography reliably predict severe pulmonary regurgitation as quantified by cardiac magnetic resonance. J Am Soc Echocardiogr 2010; 23:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/25\">",
"      Iriart X, Montaudon M, Lafitte S, et al. Right ventricle three-dimensional echography in corrected tetralogy of fallot: accuracy and variability. Eur J Echocardiogr 2009; 10:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/26\">",
"      Greutmann M, Tobler D, Biaggi P, et al. Echocardiography for assessment of right ventricular volumes revisited: a cardiac magnetic resonance comparison study in adults with repaired tetralogy of Fallot. J Am Soc Echocardiogr 2010; 23:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/27\">",
"      Greutmann M, Tobler D, Biaggi P, et al. Echocardiography for assessment of regional and global right ventricular systolic function in adults with repaired tetralogy of Fallot. Int J Cardiol 2012; 157:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/28\">",
"      Shamberger MS, Garrell AG, Parikh SR, et al. Use of peak echocardiographic Doppler gradient across ventricular septal defects underestimates right sided pressures in patients with \"sloped\" Doppler signals (abstract). J Am Soc Echocardiogr 1999; 12:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/29\">",
"      Niwa K, Siu SC, Webb GD, Gatzoulis MA. Progressive aortic root dilatation in adults late after repair of tetralogy of Fallot. Circulation 2002; 106:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/30\">",
"      Nagy CD, Alejo DE, Corretti MC, et al. Tetralogy of fallot and aortic root dilation: a long-term outlook. Pediatr Cardiol 2013; 34:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/31\">",
"      Schertpong RWC, Mollema SA, Blom NA, et al. Right ventricular peak systolic longitudinal strain is a sensitive marker for right ventricular deterioration in adult patients with Tetralogy of Fallot. Int J Cardovasc Imaging 2009; 25:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/32\">",
"      Solarz DE, Witt SA, Glascock BJ, et al. Right ventricular strain rate and strain analysis in patients with repaired tetralogy of Fallot: possible interventricular septal compensation. J Am Soc Echocardiogr 2004; 17:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/33\">",
"      Weidemann F, Eyskens B, Mertens L, et al. Quantification of regional right and left ventricular function by ultrasonic strain rate and strain indexes after surgical repair of tetralogy of Fallot. Am J Cardiol 2002; 90:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/34\">",
"      Vogel M, Sponring J, Cullen S, et al. Regional wall motion and abnormalities of electrical depolarization and repolarization in patients after surgical repair of tetralogy of Fallot. Circulation 2001; 103:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/35\">",
"      Cheung EW, Liang XC, Lam WW, Cheung YF. Impact of right ventricular dilation on left ventricular myocardial deformation in patients after surgical repair of tetralogy of fallot. Am J Cardiol 2009; 104:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/36\">",
"      Tzemos N, Harris L, Carasso S, et al. Adverse left ventricular mechanics in adults with repaired tetralogy of Fallot. Am J Cardiol 2009; 103:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/37\">",
"      Eyskens B, Brown SC, Claus P, et al. The influence of pulmonary regurgitation on regional right ventricular function in children after surgical repair of tetralogy of Fallot. Eur J Echocardiogr 2010; 11:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/38\">",
"      van der Hulst AE, Delgado V, Holman ER, et al. Relation of left ventricular twist and global strain with right ventricular dysfunction in patients after operative \"correction\" of tetralogy of fallot. Am J Cardiol 2010; 106:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/39\">",
"      Mueller M, Rentzsch A, Hoetzer K, et al. Assessment of interventricular and right-intraventricular dyssynchrony in patients with surgically repaired tetralogy of Fallot by two-dimensional speckle tracking. Eur J Echocardiogr 2010; 11:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/40\">",
"      Gatzoulis MA, Elliott JT, Guru V, et al. Right and left ventricular systolic function late after repair of tetralogy of Fallot. Am J Cardiol 2000; 86:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/41\">",
"      Geva T, Sandweiss BM, Gauvreau K, et al. Factors associated with impaired clinical status in long-term survivors of tetralogy of Fallot repair evaluated by magnetic resonance imaging. J Am Coll Cardiol 2004; 43:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/42\">",
"      Davlouros PA, Kilner PJ, Hornung TS, et al. Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction. J Am Coll Cardiol 2002; 40:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/43\">",
"      Broberg CS, Aboulhosn J, Mongeon FP, et al. Prevalence of left ventricular systolic dysfunction in adults with repaired tetralogy of fallot. Am J Cardiol 2011; 107:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/44\">",
"      Buechel ER, Dave HH, Kellenberger CJ, et al. Remodelling of the right ventricle after early pulmonary valve replacement in children with repaired tetralogy of Fallot: assessment by cardiovascular magnetic resonance. Eur Heart J 2005; 26:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/45\">",
"      Discigil B, Dearani JA, Puga FJ, et al. Late pulmonary valve replacement after repair of tetralogy of Fallot. J Thorac Cardiovasc Surg 2001; 121:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/46\">",
"      van Straten A, Vliegen HW, Lamb HJ, et al. Time course of diastolic and systolic function improvement after pulmonary valve replacement in adult patients with tetralogy of Fallot. J Am Coll Cardiol 2005; 46:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/47\">",
"      Adamson L, Vohra HA, Haw MP. Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function? Interact Cardiovasc Thorac Surg 2009; 9:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/48\">",
"      Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol 2005; 95:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/49\">",
"      Oosterhof T, van Straten A, Vliegen HW, et al. Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. Circulation 2007; 116:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/50\">",
"      Lee C, Kim YM, Lee CH, et al. Outcomes of pulmonary valve replacement in 170 patients with chronic pulmonary regurgitation after relief of right ventricular outflow tract obstruction: implications for optimal timing of pulmonary valve replacement. J Am Coll Cardiol 2012; 60:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/51\">",
"      Eyskens B, Reybrouck T, Bogaert J, et al. Homograft insertion for pulmonary regurgitation after repair of tetralogy of fallot improves cardiorespiratory exercise performance. Am J Cardiol 2000; 85:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/52\">",
"      Therrien J, Siu SC, McLaughlin PR, et al. Pulmonary valve replacement in adults late after repair of tetralogy of fallot: are we operating too late? J Am Coll Cardiol 2000; 36:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/53\">",
"      Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation 2001; 103:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/54\">",
"      Lurz P, Coats L, Khambadkone S, et al. Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical outcome. Circulation 2008; 117:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/55\">",
"      Zahn EM, Hellenbrand WE, Lock JE, McElhinney DB. Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the u.s. Clinical trial. J Am Coll Cardiol 2009; 54:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/56\">",
"      Khambadkone S, Coats L, Taylor A, et al. Percutaneous pulmonary valve implantation in humans: results in 59 consecutive patients. Circulation 2005; 112:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/57\">",
"      Boudjemline Y, Schievano S, Bonnet C, et al. Off-pump replacement of the pulmonary valve in large right ventricular outflow tracts: a hybrid approach. J Thorac Cardiovasc Surg 2005; 129:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/58\">",
"      Mollet A, Basquin A, Stos B, Boudjemline Y. Off-pump replacement of the pulmonary valve in large right ventricular outflow tracts: a transcatheter approach using an intravascular infundibulum reducer. Pediatr Res 2007; 62:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/59\">",
"      Boone RH, Webb JG, Horlick E, et al. Transcatheter pulmonary valve implantation using the Edwards SAPIEN transcatheter heart valve. Catheter Cardiovasc Interv 2010; 75:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/60\">",
"      Schievano S, Petrini L, Migliavacca F, et al. Finite element analysis of stent deployment: understanding stent fracture in percutaneous pulmonary valve implantation. J Interv Cardiol 2007; 20:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/61\">",
"      Nordmeyer J, Lurz P, Khambadkone S, et al. Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation: acute and 1-year outcomes. Heart 2011; 97:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/62\">",
"      Kostolny M, Tsang V, Nordmeyer J, et al. Rescue surgery following percutaneous pulmonary valve implantation. Eur J Cardiothorac Surg 2008; 33:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/63\">",
"      Dohlen G, Chaturvedi RR, Benson LN, et al. Stenting of the right ventricular outflow tract in the symptomatic infant with tetralogy of Fallot. Heart 2009; 95:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/64\">",
"      Harrison DA, Siu SC, Hussain F, et al. Sustained atrial arrhythmias in adults late after repair of tetralogy of fallot. Am J Cardiol 2001; 87:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/65\">",
"      Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 2000; 356:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/66\">",
"      Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. Circulation 2010; 122:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/67\">",
"      Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol 1997; 30:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/68\">",
"      Cullen S, Celermajer DS, Franklin RC, et al. Prognostic significance of ventricular arrhythmia after repair of tetralogy of Fallot: a 12-year prospective study. J Am Coll Cardiol 1994; 23:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/69\">",
"      Dietl CA, Cazzaniga ME, Dubner SJ, et al. Life-threatening arrhythmias and RV dysfunction after surgical repair of tetralogy of Fallot. Comparison between transventricular and transatrial approaches. Circulation 1994; 90:II7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/70\">",
"      Satoh M, Aizawa Y, Murata M, et al. Electrophysiologic study of patients with ventricular dysrhythmias during long-term follow-up after repair of tetralogy of Fallot. Jpn Heart J 1988; 29:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/71\">",
"      Downar E, Harris L, Kimber S, et al. Ventricular tachycardia after surgical repair of tetralogy of Fallot: results of intraoperative mapping studies. J Am Coll Cardiol 1992; 20:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/72\">",
"      Misaki T, Tsubota M, Watanabe G, et al. Surgical treatment of ventricular tachycardia after surgical repair of tetralogy of Fallot. Relation between intraoperative mapping and histological findings. Circulation 1994; 90:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/73\">",
"      Burton ME, Leon AR. Radiofrequency catheter ablation of right ventricular outflow tract tachycardia late after complete repair of tetralogy of Fallot using the pace mapping technique. Pacing Clin Electrophysiol 1993; 16:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/74\">",
"      Hokanson JS, Moller JH. Significance of early transient complete heart block as a predictor of sudden death late after operative correction of tetralogy of Fallot. Am J Cardiol 2001; 87:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/75\">",
"      Nollert GD, D&auml;britz SH, Schmoeckel M, et al. Risk factors for sudden death after repair of tetralogy of Fallot. Ann Thorac Surg 2003; 76:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/76\">",
"      Garson A Jr, Randall DC, Gillette PC, et al. Prevention of sudden death after repair of tetralogy of Fallot: treatment of ventricular arrhythmias. J Am Coll Cardiol 1985; 6:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/77\">",
"      Chen D, Moller JH. Comparison of late clinical status between patients with different hemodynamic findings after repair of tetralogy of Fallot. Am Heart J 1987; 113:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/78\">",
"      Steeds RP, Oakley D. Predicting late sudden death from ventricular arrhythmia in adults following surgical repair of tetralogy of Fallot. QJM 2004; 97:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/79\">",
"      Gatzoulis MA, Till JA, Somerville J, Redington AN. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation 1995; 92:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/80\">",
"      Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation 2004; 109:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/81\">",
"      Nollert G, Fischlein T, Bouterwek S, et al. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. J Am Coll Cardiol 1997; 30:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/82\">",
"      Garson A Jr, McNamara DG. Sudden death in a pediatric cardiology population, 1958 to 1983: relation to prior arrhythmias. J Am Coll Cardiol 1985; 5:134B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/83\">",
"      Goldner BG, Cooper R, Blau W, Cohen TJ. Radiofrequency catheter ablation as a primary therapy for treatment of ventricular tachycardia in a patient after repair of tetralogy of Fallot. Pacing Clin Electrophysiol 1994; 17:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/84\">",
"      Biblo LA, Carlson MD. Transcatheter radiofrequency ablation of ventricular tachycardia following surgical correction of tetralogy of Fallot. Pacing Clin Electrophysiol 1994; 17:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/85\">",
"      Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation 2008; 117:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/86\">",
"      Yap SC, Roos-Hesselink JW, Hoendermis ES, et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study. Eur Heart J 2007; 28:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/87\">",
"      Kurlan R, Krall RL, Deweese JA. Vertebrobasilar ischemia after total repair of tetralogy of Fallot: significance of subclavian steal created by Blalock-Taussig anastomosis. Vertebrobasilar ischemia after correction of tetralogy of Fallot. Stroke 1984; 15:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/88\">",
"      Tennant PW, Pearce MS, Bythell M, Rankin J. 20-year survival of children born with congenital anomalies: a population-based study. Lancet 2010; 375:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/89\">",
"      Lindberg HL, Saatvedt K, Seem E, et al. Single-center 50 years' experience with surgical management of tetralogy of Fallot. Eur J Cardiothorac Surg 2011; 40:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/90\">",
"      Hickey EJ, Veldtman G, Bradley TJ, et al. Functional health status in adult survivors of operative repair of tetralogy of fallot. Am J Cardiol 2012; 109:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/91\">",
"      Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/92\">",
"      Babu-Narayan SV, Kilner PJ, Li W, et al. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome. Circulation 2006; 113:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/93\">",
"      H&ouml;vels-G&uuml;rich HH, Konrad K, Skorzenski D, et al. Long-term neurodevelopmental outcome and exercise capacity after corrective surgery for tetralogy of Fallot or ventricular septal defect in infancy. Ann Thorac Surg 2006; 81:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/94\">",
"      Miatton M, De Wolf D, Fran&ccedil;ois K, et al. Intellectual, neuropsychological, and behavioral functioning in children with tetralogy of Fallot. J Thorac Cardiovasc Surg 2007; 133:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/95\">",
"      Marino BS, Lipkin PH, Newburger JW, et al. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. Circulation 2012; 126:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/96\">",
"      Tan JL, Gatzoulis MA, Ho SY. Aortic root disease in tetralogy of Fallot. Curr Opin Cardiol 2006; 21:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/97\">",
"      Attenhofer Jost CH, Connolly HM, Burkhart HM, et al. Tetralogy of fallot repair in patients 40 years or older. Mayo Clin Proc 2010; 85:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/98\">",
"      Veldtman GR, Connolly HM, Grogan M, et al. Outcomes of pregnancy in women with tetralogy of Fallot. J Am Coll Cardiol 2004; 44:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/99\">",
"      Singh H, Bolton PJ, Oakley CM. Pregnancy after surgical correction of tetralogy of Fallot. Br Med J (Clin Res Ed) 1982; 285:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/100\">",
"      Nissenkorn A, Friedman S, Schonfeld A, Ovadia J. Fetomaternal outcome in pregnancies after total correction of the tetralogy of Fallot. Int Surg 1984; 69:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/101\">",
"      Meijer JM, Pieper PG, Drenthen W, et al. Pregnancy, fertility, and recurrence risk in corrected tetralogy of Fallot. Heart 2005; 91:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/102\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/103\">",
"      Balci A, Drenthen W, Mulder BJ, et al. Pregnancy in women with corrected tetralogy of Fallot: occurrence and predictors of adverse events. Am Heart J 2011; 161:307.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/105\">",
"      Burn J, Brennan P, Little J, et al. Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study. Lancet 1998; 351:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/106\">",
"      Beauchesne LM, Warnes CA, Connolly HM, et al. Prevalence and clinical manifestations of 22q11.2 microdeletion in adults with selected conotruncal anomalies. J Am Coll Cardiol 2005; 45:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/7/28794/abstract/107\">",
"      Gill HK, Splitt M, Sharland GK, Simpson JM. Patterns of recurrence of congenital heart disease: an analysis of 6,640 consecutive pregnancies evaluated by detailed fetal echocardiography. J Am Coll Cardiol 2003; 42:923.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5770 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.211.0.116-039B397C7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28794=[""].join("\n");
var outline_f28_7_28794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H69025778\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11096360\">",
"      Tet spells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69025840\">",
"      - Blalock-Taussig shunt",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69025847\">",
"      - Intracardiac repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Short-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98216791\">",
"      POSTOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2174495\">",
"      Pulmonary insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2174480\">",
"      RV function and size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2175884\">",
"      Aortic root and valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2175891\">",
"      New echocardiographic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      POSTOPERATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic pulmonary regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pulmonary valve replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Residual right ventricular outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atrial tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ventricular tachyarrhythmias and SCD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Electrophysiologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Course and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Subclavian steal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LONG-TERM OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88361110\">",
"      Mortality and cardiac morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Neurodevelopmental outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TETRALOGY OF FALLOT IN THE ADULT PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88360281\">",
"      Primary repair in adulthood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69023439\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69023655\">",
"      - Congenital heart disease in the fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69025778\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5770\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5770|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/35/40501\" title=\"figure 1\">",
"      Anatomy of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/31/28145\" title=\"figure 2\">",
"      Surgical repair TOF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5770|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=related_link\">",
"      Management and evaluation of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=related_link\">",
"      Medical management of cyanotic congenital heart disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/25/2450?source=related_link\">",
"      Patient information: Tetralogy of Fallot (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=related_link\">",
"      Subclavian steal syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_7_28795="Burn nutr RDI";
var content_f28_7_28795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Caloric requirements for children based on the Recommended Daily Intake (kcal per day)*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Modifier*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 to 6 months",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        M and F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 months to 1 year",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        M and F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3 years",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        M and F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 to 10 years",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        M and F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11 to 14 years",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11 to 14 years",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;15 years",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        M and F",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     M: males; F: females.",
"     <br>",
"      * RDI (kcal per day) = modifier (weight in kilograms).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Saffle, JR, Graves, C. Nutritional support of the burned patient. In: Total Burn Care: 3rd Edition, Herndon, DN (Ed), Saunders Elsevier, Philadelphia, PA 2007. p.398.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28795=[""].join("\n");
var outline_f28_7_28795=null;
var title_f28_7_28796="Occupational asthma";
var content_f28_7_28796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation and management of work aggravated asthma and occupational asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Potential for workplace-related symptoms:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recognized sensitizers (eg, isocyanates, plant or animal products).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Irritants* or physical stimuli (eg, cold/heat, dust, humidity).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coworkers may have similar symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Patterns of symptoms (in relation to work exposures):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Improvement occurs during vacations or days off (may take a week or more).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Symptoms may be immediate (&lt;1 hour), delayed (most commonly, 2-8 hours after exposure), or nocturnal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Initial symptoms may occur after high-level exposure (eg, spill).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Documentation of work-relatedness of airflow limitation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serial charting for 2-3 weeks (2 weeks at work and up to 1 week off work, as needed to identify or exclude work-related changes in PEF):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Record when symptoms and exposures occur.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Record when a bronchodilator is used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Measure and record peak flow (or FEV",
"        <sub>",
"         1",
"        </sub>",
"        ) every 2 hours while awake.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunologic tests.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Referral for further confirmatory evaluation (eg, bronchial challenges).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Work-aggravated asthma:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Work with onsite health care providers or managers/supervisors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discuss avoidance, ventilation, respiratory protection, tobacco smoke-free environment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Occupationally induced asthma:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recommend complete cessation of exposure to initiating agent.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in 1 second; PEF: peak expiratory flow.",
"     <br>",
"      * Material Safety Data Sheets may be helpful for identifying respiratory irritants, but many sensitizers are not listed.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28796=[""].join("\n");
var outline_f28_7_28796=null;
var title_f28_7_28797="ANA disease associations II";
var content_f28_7_28797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of different antinuclear antibodies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"8\" rowspan=\"1\">",
"       Antibody",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       PCNA",
"      </td>",
"      <td class=\"subtitle2\">",
"       Scl-70",
"      </td>",
"      <td class=\"subtitle2\">",
"       PM-1",
"      </td>",
"      <td class=\"subtitle2\">",
"       Mi-1",
"      </td>",
"      <td class=\"subtitle2\">",
"       Jo-1",
"      </td>",
"      <td class=\"subtitle2\">",
"       Ku",
"      </td>",
"      <td class=\"subtitle2\">",
"       Nucleoli",
"      </td>",
"      <td class=\"subtitle2\">",
"       Centromere",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       SLE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       95",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Drug LE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       RA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Scleroderma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       15-20",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       54",
"      </td>",
"      <td>",
"       25-30",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       high",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       PM/DM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       30-50",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       30-50",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Sj&ouml;gren's",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Sen: sensitivity; Spec: specificity.",
"     <br>",
"      Other associations: Centromere: Limited systemic sclerosis (CREST syndrome).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28797=[""].join("\n");
var outline_f28_7_28797=null;
var title_f28_7_28798="MVAC regimen";
var content_f28_7_28798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    MVAC chemotherapy for metastatic urothelial carcinoma",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        <p>",
"         Cycle length: 28 days.",
"        </p>",
"        Total cycles: 6.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Methotrexate",
"        </strong>",
"       </td>",
"       <td>",
"        30 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in normal saline (NS) and administer as a slow IV push.",
"       </td>",
"       <td>",
"        Days 1, 15, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vinblastine",
"        </strong>",
"       </td>",
"       <td>",
"        3 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Administer IV push over one minute.",
"       </td>",
"       <td>",
"        Days 2, 15, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doxorubicin",
"        </strong>",
"       </td>",
"       <td>",
"        30 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 50 mL NS and administer over three to five minutes.",
"       </td>",
"       <td>",
"        Day 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        70 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL NS and administer over two hours. Do not administer with aluminum needles or sets.",
"       </td>",
"       <td>",
"        Day 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Induction of diuresis using intravenous NS minimizes the risk of cisplatin nephrotoxicity. Fluid administration should be adequate to establish a urine flow of at least 100 mL/hour for two hours prior to and two hours after cisplatin administration. There are a number of alternative hydration regimens. One approach is to administer 1 liter of NS over two to three hours prior to cisplatin administration and a minimum of 500 mL either with or following the cisplatin administration. Supplementation with magnesium and potassium may be required depending upon the serum electrolytes. Some centers give mannitol (12.5 gm) with the cisplatin to encourage diuresis. The addition of furosemide is generally not required unless there is evidence of fluid overload or insufficient urine output. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Both doxorubicin and vinblastine are vesicants and can cause significant tissue damage if extravasation occurs. For peripheral infusions of chemotherapy, the IV line should be recently started, and the vein selected should be large and intact, with good blood return established prior to starting the infusion. Cisplatin is classified as an irritant at low concentrations (less than 0.5 mg/mL) but can cause necrosis at higher concentrations if infiltrated subcutaneously",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        The risk of febrile neutropenia in two trials was 10 and 14 percent, respectively",
"        <sup>",
"         [1,2]",
"        </sup>",
"        .The decision to use primary prophylaxis with hematopoietic growth factors should be based upon individual risk factors for complications from prolonged neutropenia (age over 65, poor performance status, prior febrile neutropenia, large radiation ports, use of combined chemoradiotherapy, cytopenias due to marrow involvement, poor nutritional status, open wounds/active infection, renal/hepatic dysfunction, and other serious comorbidities). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for preexisting baseline liver or renal dysfunction:",
"        </strong>",
"        Adjustment of initial methotrexate, vinblastine, and doxorubicin doses may be needed for patients with preexisting liver dysfunction. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". Patients with a measured creatinine clearance less than 60 mL/min or a serum creatinine less than 177 micromol/L (2 mg/dL) were excluded from the phase III clinical trials with this regimen",
"        <sup>",
"         [1,2]",
"        </sup>",
"        . Lower methotrexate doses may be needed in patients with preexisting renal dysfunction and in those with third space fluid collections (eg, ascites, pleural effusion). Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Preexisting cardiac disease:",
"        </strong>",
"        For patients with preexisting cardiac disease, we suggest the use of dexrazoxane as an adjunctive agent with doxorubicin to prevent the development of or worsening of cardiotoxicity. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Serum basic metabolic panel (creatinine and electrolytes) daily during treatment and prior to each subsequent treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Serum liver and renal function prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess left ventricular ejection fraction prior to treatment initiation and as clinically indicated during therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Subsequent cycles are delayed until the WBC count is greater than 3000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is greater than 100,000/mm",
"        <sup>",
"         3[1]",
"        </sup>",
"        . The methotrexate and vinblastine doses on days 15 and 22 should be delayed for a WBC &lt;3000/mm",
"        <sup>",
"         3",
"        </sup>",
"        or a platelet count &lt;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . Methotrexate and doxorubicin doses should be reduced by 33 percent in patients who have a nadir WBC less than 2000/mm",
"        <sup>",
"         3[1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        The manufacturer recommends a dose reduction of vinblastine by 1 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        in patients with severe neurotoxicity",
"        <sup>",
"         [4]",
"        </sup>",
"        . Neuropathy usually is seen after cumulative doses of cisplatin beyond 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Mucositis:",
"        </strong>",
"        Doses of methotrexate should be reduced by 33 percent in patients who develop grade 3 or grade 4 mucositis",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiotoxicity:",
"        </strong>",
"        Doxorubicin should be discontinued for patients who develop evidence of heart failure",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for renal dysfunction:",
"        </strong>",
"        Dose reductions are required for cisplatin in renal insufficiency. It is recommended that the cisplatin dose be reduced by 25 percent for creatinine clearance 10 to 50 mL/min and 50 percent for creatinine clearance less than 10 mL/min",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; WBC: white blood cell count.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Loehrer PJ, et al. J Clin Oncol 1992; 10:1066.",
"       </li>",
"       <li>",
"        van der Maase H, et al. J Clin Oncol 2000; 18:3068.",
"       </li>",
"       <li>",
"        Platinol (cisplatin) injection, powder, lyophilized, for solution. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"       </li>",
"       <li>",
"        Vinblastine injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_7_28798=[""].join("\n");
var outline_f28_7_28798=null;
var title_f28_7_28799="Split urine collection for orthostatic proteinuria";
var content_f28_7_28799=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/7/28799/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28799/contributors\" id=\"au8355\">",
"       Brad H Rovin, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/7/28799/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28799/contributors\" id=\"se49\">",
"       Richard J Glassock, MD, MACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/7/28799/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/7/28799/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?28/7/28799?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     A split urine test is used to determine whether the protein in your urine is caused by a condition called orthostatic proteinuria. For reasons that are not well understood, proteinuria (protein in the urine) occurs in some people while standing or sitting but not while lying down.",
"    </p>",
"    <p>",
"     Orthostatic proteinuria is a harmless condition that can occur in young people. Generally, no further testing or treatment is necessary after diagnosis. More detailed information about orthostatic proteinuria is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17655?source=see_link\">",
"      \"Orthostatic (postural) proteinuria\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      EQUIPMENT",
"     </span>",
"    </p>",
"    <p>",
"     You will need to collect all of your urine for 24 hours. Pick a day when this would be convenient. Men may want to buy an inexpensive urinal for easy collection; women may buy an inexpensive urine hat, which fits over the toilet.",
"    </p>",
"    <p>",
"     You will also need two jugs and a funnel. Two half gallon plastic jugs (eg, milk jugs), thoroughly rinsed, are adequate. Label the two jugs:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Daytime urine",
"      </li>",
"      <li>",
"       Nighttime urine",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     Perform the following steps on the day that you are going to collect the urine.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       When you first get up, urinate and throw away this urine.",
"      </li>",
"      <li>",
"       For the rest of the day, collect all of the urine each time you go to the bathroom. Put this urine into the daytime urine jug. You can do your normal daily activities, but strenuous exercise should be avoided.",
"      </li>",
"      <li>",
"       In the evening, lie down two hours before you go to sleep. Just before sleeping, go to the bathroom for the last time and add this urine to the daytime jug. Lying down for two hours helps to avoid mixing urine made at night with urine made during the day.",
"      </li>",
"      <li>",
"       If you need to go to the bathroom during the night, be sure to collect this urine and put it in the nighttime urine jug.",
"      </li>",
"      <li>",
"       The next morning (approximately eight hours after going to sleep) collect the first morning urine and put in the nighttime urine jug.",
"      </li>",
"      <li>",
"       Take the two jugs to the laboratory.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Your doctor or nurse's office will notify you when the results are available.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285196\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285204\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285229\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285247\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Professional Level Information:",
"     </span>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17655?source=see_link\">",
"      Orthostatic (postural) proteinuria",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </p>",
"    <p>",
"     <strong>",
"      ACKNOWLEDGMENT",
"     </strong>",
"     &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Suzanne Fletcher, MD, who contributed to an earlier version of this topic review.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?28/7/28799?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f28_7_28799=[""].join("\n");
var outline_f28_7_28799=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           EQUIPMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
